<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2018 | Cochrane Library</title> <meta content="Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2018 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001031.pub4/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review - Nevitt, SJ - 2018 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001031.pub4/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD001031.pub4" name="dc.identifier" scheme="DOI"/> <meta content="Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review" name="citation_title"/> <meta content="Sarah J Nevitt" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="sjn16@liverpool.ac.uk" name="citation_author_email"/> <meta content="Catrin Tudur Smith" name="citation_author"/> <meta content="University of Liverpool" name="citation_author_institution"/> <meta content="Jennifer Weston" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Anthony G Marson" name="citation_author"/> <meta content="Institute of Translational Medicine, University of Liverpool" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="6" name="citation_issue"/> <meta content="10.1002/14651858.CD001031.pub4" name="citation_doi"/> <meta content="2018" name="citation_date"/> <meta content="2018/06/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001031.pub4/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001031.pub4/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD001031.pub4/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Anticonvulsants [adverse effects, *therapeutic use]; Carbamazepine [adverse effects, *therapeutic use]; Epilepsies, Partial [*drug therapy]; Epilepsy, Generalized [drug therapy]; Epilepsy, Tonic‐Clonic [*drug therapy]; Lamotrigine; Randomized Controlled Trials as Topic; Recurrence; Time Factors; Treatment Failure; Triazines [*therapeutic use]; Withholding Treatment" name="citation_keywords"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD001031.pub4&amp;doi=10.1002/14651858.CD001031.pub4&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773519000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739773548000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513680837000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513680837000"}};Liferay.authToken="QO4KtYGW";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD001031\x2epub4\x26doi\x3d10\x2e1002\x2f14651858\x2eCD001031\x2epub4\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513680837000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","ru","ms","fr","fa","zh_HANS"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD001031.pub4",title:"Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review",firstPublishedDate:"Jun 28, 2018 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Epilepsy Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734739000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001031.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001031.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD001031.pub4/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD001031.pub4/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001031.pub4%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD001031.PUB4" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;摘要&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;},{&quot;language&quot;:&quot;ru&quot;,&quot;title&quot;:&quot;Резюме на простом языке&quot;},{&quot;language&quot;:&quot;zh_HANS&quot;,&quot;title&quot;:&quot;简语概要&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD001031.pub4/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD001031.PUB4" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD001031.pub4/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD001031.pub4/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>7064 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD001031.pub4" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-abs-0004"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0105"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0029"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0030"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0035"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0036"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0063"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-sec-0099"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/appendices#CD001031-sec-0110"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/table_n/CD001031StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/table_n/CD001031StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2018 The Cochrane Collaboration. Published by John Wiley &amp; Sons, Ltd." data-creative-commons="false" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> <div class="inline-status-wrapper"> <ul class="cochrane-status"> <li aria-label="A new search for studies has been conducted." class="status-item up-to-date custom-tooltip" data-status="newsearch" title="A new search for studies has been conducted."> <a class="btn secondary" href="information#history">New search</a> </li> </ul> </div> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review </h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#CD001031-cr-0002"><i class="icon corresponding-author fa fa-envelope"></i>Sarah J Nevitt</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#CD001031-cr-0003">Catrin Tudur Smith</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#CD001031-cr-0004">Jennifer Weston</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information#CD001031-cr-0005">Anthony G Marson</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information/en#CD001031-sec-0117">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 June 2018 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD001031.pub4">https://doi.org/10.1002/14651858.CD001031.pub4</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD001031-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001031-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001031-abs-0003">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001031-abs-0009">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001031-abs-0002">Français</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001031-abs-0011">简体中文</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD001031-abs-0001" lang="en"> <section id="CD001031-sec-0001"> <h3 class="title" id="CD001031-sec-0001">Background</h3> <p>This is an updated version of the original Cochrane Review published in Issue 11, 2006 of the <i>Cochrane Database of Systematic Reviews</i>. </p> <p>Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. It is believed that with effective drug treatment up to 70% of individuals with active epilepsy have the potential to become seizure‐free, and to go into long‐term remission shortly after starting drug therapy with a single antiepileptic drug (AED) in monotherapy. </p> <p>The correct choice of first‐line AED for individuals with newly diagnosed seizures is of great importance. It is important that the choice of AEDs for an individual is made using the highest quality evidence regarding the potential benefits and harms of the various treatments. </p> <p>Carbamazepine or lamotrigine are recommended as first‐line treatments for new onset focal seizures and as a first‐ or second‐line treatment for generalised tonic‐clonic seizures. Performing a synthesis of the evidence from existing trials will increase the precision of the results for outcomes relating to efficacy and tolerability and may assist in informing a choice between the two drugs. </p> </section> <section id="CD001031-sec-0002"> <h3 class="title" id="CD001031-sec-0002">Objectives</h3> <p>To review the time to treatment failure, remission and first seizure with lamotrigine compared to carbamazepine when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised) or generalised onset tonic‐clonic seizures (with or without other generalised seizure types). </p> </section> <section id="CD001031-sec-0003"> <h3 class="title" id="CD001031-sec-0003">Search methods</h3> <p>We conducted the first searches for this review in 1997. For the most recent update, we searched the Cochrane Epilepsy Group Specialized Register, the Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO), MEDLINE, Clinical Trials.gov and the WHO International Clinical Trials Registry Platform on 26 February 2018, without language restrictions </p> </section> <section id="CD001031-sec-0004"> <h3 class="title" id="CD001031-sec-0004">Selection criteria</h3> <p>Randomised controlled trials comparing monotherapy with either carbamazepine or lamotrigine in children or adults with focal onset seizures or generalised onset tonic‐clonic seizures </p> </section> <section id="CD001031-sec-0005"> <h3 class="title" id="CD001031-sec-0005">Data collection and analysis</h3> <p>This was an individual participant data (IPD) review. Our primary outcome was time to treatment failure and our secondary outcomes were time to first seizure post randomisation, time to six‐month, 12‐month and 24‐month remission, and incidence of adverse events. We used Cox proportional hazards regression models to obtain trial‐specific estimates of hazard ratios (HRs) with 95% confidence intervals (CIs), using the generic inverse variance method to obtain the overall pooled HR and 95% CI. </p> </section> <section id="CD001031-sec-0006"> <h3 class="title" id="CD001031-sec-0006">Main results</h3> <p>We included 14 trials in this review. Individual participant data were available for 2572 participants out of 3787 eligible individuals from nine out of 14 trials: 68% of the potential data. For remission outcomes, a HR of less than one indicated an advantage for carbamazepine; and for first seizure and treatment failure outcomes, a HR of less than one indicated an advantage for lamotrigine. </p> <p>The main overall results were: time to treatment failure for any reason related to treatment (pooled HR adjusted for seizure type: 0.71, 95% CI 0.62 to 0.82, moderate‐quality evidence), time to treatment failure due to adverse events (pooled HR adjusted for seizure type: 0.55 (95% CI 0.45 to 0.66, moderate‐quality evidence), time to treatment failure due to lack of efficacy (pooled HR for all participants: 1.03 (95% CI 0.75 to 1.41), moderate‐quality evidence) showing a significant advantage for lamotrigine compared to carbamazepine in terms of treatment failure for any reason related to treatment and treatment failure due to adverse events, but no different between drugs for treatment failure due to lack of efficacy. </p> <p>Time to first seizure (pooled HR adjusted for seizure type: 1.26, 95% CI 1.12 to 1.41, high‐quality evidence) and time to six‐month remission (pooled HR adjusted for seizure type: 0.86, 95% CI 0.76 to 0.97, high‐quality evidence), showed a significant advantage for carbamazepine compared to lamotrigine for first seizure and six‐month remission. We found no difference between the drugs for time to 12‐month remission (pooled HR for all participants 0.91, 95% CI 0.77 to 1.07, high‐quality evidence) or time to 24‐month remission (HR for all participants 1.00, 95% CI 0.80 to 1.25, high‐quality evidence), however only two trials followed up participants for more than one year so evidence is limited. </p> <p>The results of this review are applicable mainly to individuals with focal onset seizures; 88% of included individuals experienced seizures of this type at baseline. Up to 50% of the limited number of individuals classified as experiencing generalised onset seizures at baseline may have had their seizure type misclassified, therefore we recommend caution when interpreting the results of this review for individuals with generalised onset seizures. </p> <p>The most commonly reported adverse events for both of the drugs across all of the included trials were dizziness, fatigue, gastrointestinal disturbances, headache and skin problems. The rate of adverse events was similar across the two drugs. </p> <p>The methodological quality of the included trials was generally good, however there is some evidence that the design choice of masked or open‐label treatment may have influenced the treatment failure and withdrawal rates of the trials. Hence, we judged the quality of the evidence for the primary outcome of treatment failure to be moderate for individuals with focal onset seizures and low for individuals with generalised onset seizures. For efficacy outcomes (first seizure, remission), we judged the quality of evidence to be high for individuals with focal onset seizures and moderate for individuals with generalised onset seizures. </p> </section> <section id="CD001031-sec-0007"> <h3 class="title" id="CD001031-sec-0007">Authors' conclusions</h3> <p>Moderate quality evidence indicates that treatment failure for any reason related to treatment or due to adverse events occurs significantly earlier on carbamazepine than lamotrigine, but the results for time to first seizure suggested that carbamazepine may be superior in terms of seizure control. The choice between these first‐line treatments must be made with careful consideration. We recommend that future trials should be designed to the highest quality possible with consideration of masking, choice of population, classification of seizure type, duration of follow‐up, choice of outcomes and analysis, and presentation of results. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD001031-abs-0004" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD001031-abs-0004">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD001031-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD001031-abs-0010">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD001031-abs-0007">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD001031-abs-0006">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="full/ru#CD001031-abs-0005">Русский</a> </li> <li class="section-language"> <a class="" href="full/zh_HANS#CD001031-abs-0012">简体中文</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD001031-abs-0004" lang="en"> <h3>Lamotrigine versus carbamazepine monotherapy (single medication treatment) for epilepsy</h3> <p>This is an updated version of the Cochrane Review previously published in Issue 11, 2016 of the <i>Cochrane Database of Systematic Reviews</i>. </p> <p><b>Background</b> </p> <p>Epilepsy is a common neurological disorder in which abnormal electrical discharges from the brain cause recurrent seizures. We studied two types of epileptic seizures in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). Focal seizures may become generalised (secondary generalisation) and move from one part of the brain throughout the brain. For around 70% of people with epilepsy, a single antiepileptic medication can control generalised onset or focal onset seizures. </p> <p>This review applies to people with focal seizures (with or without secondary generalisation) and people with generalised tonic‐clonic seizures, a specific generalised seizure type. This review does not apply to people with other generalised seizure types such as absence seizures or myoclonic seizures, as the recommended treatments for these seizure types are different. </p> <p><b>Objective</b> </p> <p>Carbamazepine and lamotrigine are first‐choice treatments for individuals with recently diagnosed epilepsy. The aim of this review was to compare how effective these drugs are at controlling seizures, to find out if they are associated with side effects that may result in individuals stopping the medication, and to inform a choice between these medications. </p> <p><b>Methods</b> </p> <p>The last search for trials was in February 2018. We assessed the evidence from 14 randomised controlled trials comparing lamotrigine with carbamazepine. We were able to combine information for 2572 people from nine of the 14 trials; for the remaining 1215 people from five trials, information was not available to use in this review. </p> <p><b>Results</b> </p> <p>The results of the review suggest that people are more likely to withdraw earlier from carbamazepine than lamotrigine treatment. The most common medicine‐related reason for withdrawal was side effects: 52% of total withdrawals in participants on carbamazepine and 36% of total withdrawals in participants on lamotrigine. The second most common medicine‐related cause for withdrawal was seizure recurrence: 58 of 719 total withdrawals (8%) on carbamazepine and 105 of 697 total withdrawals (15%) on lamotrigine. </p> <p>The results suggest that recurrence of seizures after starting treatment with lamotrigine may happen earlier than treatment with carbamazepine. They also suggest that freedom from seizures for a period of six months may occur earlier on carbamazepine than lamotrigine. The majority of the people included in the 14 trials (88%) experienced focal seizures, so the results of this review apply mainly to people with this seizure type. </p> <p>The most common side effects reported by participants during the trials were dizziness, fatigue, gastrointestinal problems, headaches and skin problems. These side effects were reported a similar number of times by people taking lamotrigine or carbamazepine. </p> <p><b>Quality of the evidence</b> </p> <p>For people with focal onset seizures, we judged the quality of the evidence to be high for the outcomes of seizure recurrence and remission of seizures and we judged the quality of the evidence to be moderate for the outcome of treatment failure. The design of the trials (specifically, whether the people and treating clinicians knew which medication they were taking) may have influenced the rates of withdrawal from treatments. Up to 50% of people in the trials used in our results may have been wrongly classified as having generalised seizures; for people with generalised onset seizures, we judged the quality of the evidence to be moderate for the outcomes of seizure recurrence and remission of seizures and low quality for the outcome of treatment failure. </p> <p><b>Conclusions</b> </p> <p>For people with focal onset seizures, lamotrigine and carbamazepine are effective treatments and a choice between these two treatments must be made carefully. More information is needed for people with generalised onset seizures. We recommend that all future trials comparing these medications, or any other antiepileptic medications, should be designed using high‐quality methods. Seizure types of people included in trials should also be classified very carefully to ensure that the results are also of high quality. </p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD001031-sec-0105" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD001031-sec-0105"></div> <h3 class="title" id="CD001031-sec-0106">Implications for practice</h3> <section id="CD001031-sec-0106"> <p>Current UK guidelines recommend carbamazepine or lamotrigine as first‐line treatment for adults and children with new onset focal seizures and sodium valproate for adults and children with new onset generalised seizures (<a href="./references#CD001031-bbs2-0064" title="National Institute for Health and Care Excellence. Clinical Guidance 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence2012. ">NICE 2012</a>). </p> <p>For individuals with new onset focal seizures, the moderate‐quality evidence provided by this review suggests that lamotrigine is likely to be a more effective drug than carbamazepine in terms of treatment retention (treatment failure for any reason related to treatment or due to adverse events). However, high‐quality evidence provided by this review suggests that individuals are likely to achieve earlier remission and later seizure recurrence when taking carbamazepine compared to lamotrigine. Therefore a choice between these two first‐line treatments for individuals with new onset focal seizures must be carefully considered, taking the personal circumstances of an individual into account. </p> <p>For individuals with new onset generalised seizures, the evidence in the review is limited and of moderate to low quality due to small numbers of participants with certain generalised seizure types recruited into the included trials. There is evidence that carbamazepine may exacerbate some generalised seizure types so should be used with caution in individuals with this seizure type (<a href="./references#CD001031-bbs2-0052" title="LiporaceJD , SperlingMR , DichterMA . Absence seizures and carbamazepine in adults. Epilepsia1994;35(5):1026‐8. ">Liporace 1994</a>; <a href="./references#CD001031-bbs2-0078" title="ShieldsWD , SaslowE . Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology1983;33:1487‐9. ">Shields 1983</a>; <a href="./references#CD001031-bbs2-0079" title="SneadOC , HoseyLC . Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine1985;313:916‐21. ">Snead 1985</a>). Lamotrigine may be an effective treatment option for new onset generalised seizures, but more evidence is required to confirm this. </p> </section> <h3 class="title" id="CD001031-sec-0107">Implications for research</h3> <section id="CD001031-sec-0107"> <p>This review highlights the need for the design of future antiepileptic drug monotherapy trials that recruit individuals with specific epilepsy syndromes to be powered to detect a difference between particular antiepileptic drugs. An approach likely to reflect and inform clinical practice, as well as being statistically powerful, would be to recruit heterogeneous populations for whom epilepsy syndromes have been adequately defined, with testing for interaction between treatment and epilepsy syndrome. In view of potential problems of misclassification, syndromes will have to be well defined, with adequate checking mechanisms to ensure that classifications are accurate and a system to recognise uncertainty surrounding epilepsy syndromes in individuals within trials. It is also important that future trials are of a sufficient duration to measure long‐term effectiveness of antiepileptic drugs (treatments that will be life‐long for many individuals with epilepsy), as well as psychosocial, quality‐of‐life and health economic outcomes. </p> <p>Consideration is also required in the design of a trial regarding whether to blind participants and outcome assessors to treatment allocation. While an open‐label design is a more pragmatic and practical approach for large, long‐term trials, when trials involve a new intervention compared to an established 'standard' intervention, masking of treatment may be important to avoid preconceptions over the relative effectiveness of the drugs. </p> <p>The choice of outcomes at the design stage of a trial and the presentation of the results of outcomes, particularly of a time‐to‐event nature, require very careful consideration. While the majority of trials of a monotherapy design record an outcome measuring efficacy (seizure control) and an outcome measuring tolerability (adverse events), there is little uniformity between the definition of the outcomes and the reporting of the summary statistics related to the outcomes (<a href="./references#CD001031-bbs2-0065" title="NolanSJ , SuttonL , MarsonA , Tudur SmithC . Consistency of outcome and statistical reporting of time‐to‐event data: the impact on Cochrane Reviews and meta‐analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health, Quebec City. 2013:114‐5. ">Nolan 2013a</a>), making an aggregate data approach to meta‐analysis in reviews of monotherapy trials impossible. Where trial authors cannot or will not make individual participant data available for analysis, we are left with no choice but to exclude a proportion of relevant evidence from the review, which may impact upon the interpretation of the results of the review and the applicability of the evidence and conclusions. The International League Against Epilepsy recommends that trials of a monotherapy design should adopt a primary effectiveness outcome of time to treatment failure (i.e. retention time) and should be of a duration of at least 48 weeks to allow for assessment of longer‐term outcomes, such as remission (<a href="./references#CD001031-bbs2-0045" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>; <a href="./references#CD001031-bbs2-0046" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">ILAE 2006</a>). If trials followed these recommendations, an aggregate data approach to meta‐analysis may be feasible, reducing the resources and time required from an individual participant data approach. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD001031-sec-0029" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD001031-sec-0029"></div> <div class="table" id="CD001031-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: lamotrigine compared with carbamazepine for epilepsy (primary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine compared with carbamazepine for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure types) </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> lamotrigine </p> <p><b>Comparison:</b> carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lamotrigine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1144 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1813 days (669 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.71 (0.62 to 0.82)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2481 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine.</p> <p>Treatment failure due to adverse events also occurred significantly earlier on carbamazepine compared to lamotrigine: HR 0.54 (95% CI 0.45 to 0.65, P&lt;0.00001). </p> <p>There was no difference between lamotrigine and carbamazepine in terms of treatment failure due to lack of efficacy: HR 1.03 (95% CI 0.75 to 1.41, P=0.86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1149 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1699 days (550 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.74 (0.64 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2182 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine.</p> <p>Treatment failure due to adverse events also occurred significantly earlier on carbamazepine compared to lamotrigine: HR 0.56 (95% CI 0.45 to 0.68, P&lt;0.00001). </p> <p>Treatment failure due to lack of efficacy was not calculated for focal onset seizures subgroup due to small numbers of individuals withdrawing from treatment for lack of efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 0 to 1446 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 57 days in the carbamazepine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 510 days (453 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.51 (0.33 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 (6 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> <p>Treatment failure due to adverse events also occurred significantly earlier on carbamazepine compared to lamotrigine: HR 0.49 (95% CI 0.27 to 0.88, P=0.02). </p> <p>Treatment failure due to lack of efficacy was not calculated for focal onset seizures subgroup due to small numbers of individuals withdrawing from treatment for lack of efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the carbamazepine and lamotrigine groups are calculated at the median time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to treatment failure' between the treatment groups. </p> <p>** The 25th percentile of time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) is presented for the subgroup with generalised seizures as less than 50% of participants failed / withdrew from treatment, therefore the median time could not be calculated. </p> <p><b>Abbreviations: 95% CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled hazard ratio for all participants adjusted for seizure type.</p> <p>b. Downgraded once due to high risk of bias due to the open‐label design of five trials included in the analysis (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>); the design of the trial may have influenced the withdrawal rates. </p> <p>c. Downgraded once due to high risk of bias due to the open‐label design of three trials included in the analysis (<a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>); the design of the trial may have influenced the withdrawal rates. </p> <p>d. Downgraded once due to potential misclassification of generalised onset seizures in up to 50% of participants in the trials. </p> </div> </td> </tr> </tfoot> </table> </div> <div class="table" id="CD001031-tbl-0002"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: lamotrigine compared with carbamazepine for epilepsy (secondary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine compared with carbamazepine for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure types) </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> lamotrigine </p> <p><b>Comparison:</b> carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)<sup>1</sup> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lamotrigine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 232 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 134 days (98 days shorter) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.26 (1.12 to 1.41)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2476 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 208 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 96 days (112 days shorter) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.29 (1.14 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2177 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 0 to 853 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 853 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 337 days (516 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.98 (0.65 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (6 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to 12‐month remission</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to 12‐month remission was 452 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to 12‐month remission was 538 days (86 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.91 (0.77 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>988 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for carbamazepine</p> <p>Time to 12‐month remission not presented by seizure type due to small numbers of participants with generalised onset seizures in the two trials </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the carbamazepine and lamotrigine groups are calculated at the median time to first seizure or time to 12‐month remission (i.e. the time to 50% of participants experiencing a first seizure or 12‐months of remission) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to first seizure' or 'time to 12‐month remission' between the treatment groups. </p> <p><b>Abbreviations: 95% CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled hazard ratio for all participants adjusted for seizure type.</p> <p>b. High risk of bias due to the open‐label design in some of the included trials, however outcomes are objective and unlikely to be influenced by knowledge of drug allocation. No downgrade made. </p> <p>c. Downgraded once due to potential misclassification of generalised onset seizures in up to 50% of participants in the trials. </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD001031-sec-0030" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD001031-sec-0030"></div> <p>This review is an update of a previously published review in the <i>Cochrane Database of Systematic Reviews</i> (Issue 11, 2016) on 'Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review' (<a href="./references#CD001031-bbs2-0085" title="GambleC , WilliamsonPR , MarsonAG . Lamotrigine versus carbamazepine monotherapy for epilepsy. Cochrane Database of Systematic Reviews2006, Issue 1. [DOI: 10.1002/14651858.CD001031.pub2] ">Gamble 2006</a>; <a href="./references#CD001031-bbs2-0086" title="NolanSJ , Tudur SmithC , WestonJ , MarsonAG . Lamotrigine versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 11. [DOI: 10.1002/14651858.CD001031.pub3] ">Nolan 2016a</a>) </p> <section id="CD001031-sec-0031"> <h3 class="title" id="CD001031-sec-0031">Description of the condition</h3> <p>Epilepsy is a common neurological condition in which abnormal electrical discharges from the brain cause recurrent unprovoked seizures. Epilepsy is a disorder of many heterogenous seizure types, with an estimated incidence of 33 to 57 per 100,000 person‐years worldwide (<a href="./references#CD001031-bbs2-0033" title="AnnegersJF , DubinskyS , CoanSP , NewmarkME , RohtL . The incidence of epilepsy and unprovoked seizures in multiethnic, urban health maintenance organizations. Epilepsia1999;40(4):502‐6. ">Annegers 1999</a>; <a href="./references#CD001031-bbs2-0044" title='HirtzD , ThurmanDJ , Gwinn‐HardyK , MohamedM , ChaudhuriAR , ZalutskyR . How common are the "common" neurologic disorders?. Neurology2007;68:326‐37. '>Hirtz 2007</a>; <a href="./references#CD001031-bbs2-0054" title="MacDonaldBK , JohnsonAL , GoodridgeDM , CockerellOC , SanderJWA , ShorvonSD . Factors predicting prognosis of epilepsy after presentation with seizures. Annals of Neurology2000;48:833‐41. ">MacDonald 2000</a>; <a href="./references#CD001031-bbs2-0071" title="OlafssonE , LudvigssonP , GudmundssonG , HesdorferD , KjartanssonO , HauserWA . Incidence of unprovoked seizures and epilepsy in Iceland and assessment of the epilepsy syndrome classification: a prospective study. Lancet Neurology2005;4:627‐34. ">Olafsson 2005</a>; <a href="./references#CD001031-bbs2-0074" title="SanderJW , ShorvonSD . Epidemiology of the epilepsies. Journal of Neurology, Neurosurgery, and Psychiatry1996;61(5):433‐43. ">Sander 1996</a>), accounting for approximately 1% of the global burden of disease (<a href="./references#CD001031-bbs2-0060" title="MurrayCJL , LopezAD . Global comparative assessments in the health sector. World Health Organization1994. ">Murray 1994</a>). The lifetime risk of epilepsy onset is estimated to be 1300 to 4000 per 100,000 person‐years (<a href="./references#CD001031-bbs2-0040" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD001031-bbs2-0047" title="Juul‐JensonP , FoldspangA . Natural history of epileptic seizures. Epilepsia1983;24:297‐312. ">Juul‐Jenson 1983</a>), and the lifetime prevalence could be as large as 70 million people worldwide (<a href="./references#CD001031-bbs2-0063" title="NgugiAK , BottomleyC , KleinschmidtI , SanderJW , NewtonCR . Estimation of the burden of active and life‐time epilepsy: a meta‐analytic approach. Epilepsia2010;51:883‐90. ">Ngugi 2010</a>). It is believed that with effective drug treatment, up to 70% of individuals with active epilepsy have the potential to go into long‐term remission shortly after starting drug therapy (<a href="./references#CD001031-bbs2-0037" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>; <a href="./references#CD001031-bbs2-0040" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD001031-bbs2-0075" title="SanderJW . The use of anti‐epileptic drugs ‐ principles and practice. Epilepsia2004;45(6):28‐34. ">Sander 2004</a>), and around 70% of individuals can achieve seizure freedom using a single antiepileptic drug (AED) in monotherapy (<a href="./references#CD001031-bbs2-0037" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>). Current National Institute for Health and Care Excellence (NICE) guidelines recommend that both adults and children with epilepsy should be treated with monotherapy wherever possible (<a href="./references#CD001031-bbs2-0064" title="National Institute for Health and Care Excellence. Clinical Guidance 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence2012. ">NICE 2012</a>). The remaining 30% of individuals experience refractory or drug‐resistant seizures, which often require treatment with combinations of antiepileptic drugs (AEDs) or alternative treatments, such as epilepsy surgery (<a href="./references#CD001031-bbs2-0049" title="KwanP , BrodieMJ . Early identification of refractory epilepsy. New England Journal of Medicine2000;342:314‐9. ">Kwan 2000</a>). </p> <p>We studied two seizure types in this review: generalised onset seizures, in which electrical discharges begin in one part of the brain and move throughout the brain; and focal onset seizures, in which the seizure is generated in and affects one part of the brain (the whole hemisphere of the brain or part of a lobe of the brain). </p> </section> <section id="CD001031-sec-0032"> <h3 class="title" id="CD001031-sec-0032">Description of the intervention</h3> <p>Carbamazepine was amongst the earliest 'traditional' medications licensed for the treatment of epileptic seizures and has been commonly used as monotherapy for focal onset and generalised onset seizures for over 30 years (<a href="./references#CD001031-bbs2-0077" title="ShakirRA . Sodium valproate, phenytoin and carbamazepine as sole anticonvulsants. The Place of Sodium Valproate in the Treatment of Epilepsy. London: Academic Press Inc (London) Ltd and the Royal Society of Medicine, 1980:7‐16. ">Shakir 1980</a>). Lamotrigine is among a 'second generation' of AEDs, licensed as monotherapy for epileptic seizures following demonstrations of efficacy compared to 'traditional' AEDs such as carbamazepine (<a href="./references#CD001031-bbs2-0034" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. ">Brodie 1995</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). </p> <p>Comparative trials have shown newer AEDs such as lamotrigine to be to be generally well tolerated as monotherapy in both adults and children, and related to fewer adverse events, fewer serious adverse events and fewer drug interactions with concomitant AEDs and other concomitant medications than 'traditional' first‐line AEDs such as carbamazepine (<a href="./references#CD001031-bbs2-0034" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. ">Brodie 1995</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0039" title="FrenchJA , KannerAM , BautistaJ , Abou‐KhalilB , BrowneT , HardenCL , et al. Appendix C: Efficacy and tolerability of the new antiepileptic drugs I: Treatment of new onset epilepsy: Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. CONTINUUM Lifelong Learning in Neurology2007;13:203‐11. ">French 2007</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). </p> <p>Evidence regarding teratogenic effects (disturbances to foetal development) of carbamazepine and lamotrigine is conflicting and uncertain. It is thought that the risk of congenital malformation may be higher for women taking carbamazepine compared to the general population (<a href="./references#CD001031-bbs2-0058" title="MeadorK , ReynoldsM , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic reviews and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81:1‐13. ">Meador 2008</a>; <a href="./references#CD001031-bbs2-0059" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry2006;77(2):193‐8. ">Morrow 2006</a>), and carbamazepine has been shown to be associated with neural tube defects (<a href="./references#CD001031-bbs2-0057" title="MatlowJ , KorenG . Is carbamazepine safe to take during pregnancy?. Canadian Family Physician2012;58:163‐4. ">Matlow 2012</a>). The risk of malformations is thought to be lower for women taking lamotrigine than carbamazepine (<a href="./references#CD001031-bbs2-0058" title="MeadorK , ReynoldsM , CreanS , FahrbachK , ProbstC . Pregnancy outcomes in women with epilepsy: a systematic reviews and meta‐analysis of published pregnancy registries and cohorts. Epilepsy Research2008;81:1‐13. ">Meador 2008</a>), but the risk of malformation may increase with an increasing dose of lamotrigine (<a href="./references#CD001031-bbs2-0059" title="MorrowJ , RusselA , GuthrieE , ParsonsL , RobertsonI , WaddellR , et al. Malformation risks of antiepileptic drugs in pregnancy: a prospective study from the UK Epilepsy and Pregnancy Register. Journal of Neurology, Neurosurgery, and Neuropsychiatry2006;77(2):193‐8. ">Morrow 2006</a>). It is unclear whether taking carbamazepine or lamotrigine during pregnancy has any negative neurodevelopmental effects on the child (<a href="./references#CD001031-bbs2-0036" title="BromleyR , WestonJ , AdabN , GreenhalghJ , SannitiA , McKayAJ , et al. Treatment for epilepsy in pregnancy: neurodevelopmental outcomes in the child. Cochrane Database of Systematic Reviews2014, Issue 10. [DOI: 10.1002/14651858.CD010236.pub2] ">Bromley 2014</a>). </p> <p>Current NICE guidelines for adults and children recommend carbamazepine or lamotrigine as first‐line treatments for new onset focal seizures and as second‐line treatments for generalised tonic‐clonic seizures (<a href="./references#CD001031-bbs2-0064" title="National Institute for Health and Care Excellence. Clinical Guidance 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence2012. ">NICE 2012</a>). Lamotrigine is considered a suitable first‐line treatment for new onset generalised seizures if sodium valproate is considered unsuitable. Carbamazepine may be a suitable second‐line treatment for generalised onset seizures but may exacerbate myoclonic or absence seizures (<a href="./references#CD001031-bbs2-0052" title="LiporaceJD , SperlingMR , DichterMA . Absence seizures and carbamazepine in adults. Epilepsia1994;35(5):1026‐8. ">Liporace 1994</a>; <a href="./references#CD001031-bbs2-0078" title="ShieldsWD , SaslowE . Myoclonic, atonic, and absence seizures following institution of carbamazepine therapy in children. Neurology1983;33:1487‐9. ">Shields 1983</a>; <a href="./references#CD001031-bbs2-0079" title="SneadOC , HoseyLC . Exacerbation of seizures in children by carbamazepine. New England Journal of Medicine1985;313:916‐21. ">Snead 1985</a>). </p> </section> <section id="CD001031-sec-0033"> <h3 class="title" id="CD001031-sec-0033">How the intervention might work</h3> <p>Antiepileptic medications suppress seizures by reducing neuronal excitability (disruption of the usual mechanisms of a neuron within the brain, which may lead to an epileptic seizure) (<a href="./references#CD001031-bbs2-0053" title="MacDonaldRL , KellyKM . Antiepileptic drug mechanisms of action. Epilepsia1995;36(Suppl 2):S2‐12. ">MacDonald 1995</a>). Lamotrigine and carbamazepine are broad‐spectrum treatments suitable for many seizure types, and both have an anticonvulsant mechanism through blocking ion channels and binding with neurotransmitter receptors, or through inhibiting the metabolism or reuptake of neurotransmitters (<a href="./references#CD001031-bbs2-0035" title="BrodieMJ , DichterMA . Antiepileptic drugs. New England Journal of Medicine1996;334(3):168‐75. ">Brodie 1996</a>; <a href="./references#CD001031-bbs2-0050" title="LeesG , LeachMJ . Studies on the mechanism of action of the novel anti‐convulsant lamotrigine (Lamictal) using primary neuroglial cultures from rat cortex. Brain Research1993;612:190‐9. ">Lees 1993</a>; <a href="./references#CD001031-bbs2-0073" title="RagsdaleDS , ScheuerT , CatterallWA . Frequency and voltage‐dependent inhibition of type IIA Na+ channels,expressed in a mammalian cell line, by local anesthetic, antiarrhythmic, and anticonvulsant drugs. Molecular Pharmacology1991;40(5):756‐65. ">Ragsdale 1991</a>). </p> </section> <section id="CD001031-sec-0034"> <h3 class="title" id="CD001031-sec-0034">Why it is important to do this review</h3> <p>With evidence that up to 70% of individuals with active epilepsy have the potential to go into long‐term remission of seizures shortly after starting drug therapy (<a href="./references#CD001031-bbs2-0037" title="CockerellOC , JohnsonAL , SanderJW , HartYM , ShorvonSD . Remission of epilepsy: results from the National General Practice Study of Epilepsy. Lancet1995;346(8968):140‐4. ">Cockerell 1995</a>; <a href="./references#CD001031-bbs2-0040" title="HauserWA , AnnegersJF , KurlandLT . Incidence of epilepsy and unprovoked seizures in Rochester, Minnesota 1935 ‐ 1984. Epilepsia1993;34:453‐68. ">Hauser 1993</a>; <a href="./references#CD001031-bbs2-0075" title="SanderJW . The use of anti‐epileptic drugs ‐ principles and practice. Epilepsia2004;45(6):28‐34. ">Sander 2004</a>), the correct choice of first‐line antiepileptic therapy for individuals with newly diagnosed seizures is of great importance. It is important that the choice of AEDs for an individual is made using the highest quality evidence regarding the potential benefits and harms of various treatments. It is also important that the effectiveness and tolerability of AEDs appropriate to given seizure types are compared to one another. </p> <p>Therefore the aim of this review is to summarise efficacy and tolerability from existing randomised controlled trials comparing lamotrigine and carbamazepine, two current first‐line recommended treatments for use in monotherapy for epileptic seizures. Performing a synthesis of the evidence from existing trials will increase the precision of the results for outcomes relating to efficacy and tolerability and may assist in informing a choice between the two drugs. </p> <p>There are difficulties in undertaking a systematic review of epilepsy monotherapy trials as the important efficacy outcomes require analysis of time‐to‐event data (for example, time to first seizure after randomisation). Although methods have been developed to synthesise time‐to‐event data using summary information (<a href="./references#CD001031-bbs2-0072" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>; <a href="./references#CD001031-bbs2-0084" title="WilliamsonPR , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(11):3337‐51. ">Williamson 2002</a>), the appropriate statistics are not commonly reported in published epilepsy trials (<a href="./references#CD001031-bbs2-0065" title="NolanSJ , SuttonL , MarsonA , Tudur SmithC . Consistency of outcome and statistical reporting of time‐to‐event data: the impact on Cochrane Reviews and meta‐analyses in epilepsy. 21st Cochrane Colloquium: Better Knowledge for Better Health, Quebec City. 2013:114‐5. ">Nolan 2013a</a>; <a href="./references#CD001031-bbs2-0083" title="WilliamsonPR , MarsonAG , TudurC , HuttonJL , ChadwickDW . Individual patient data meta‐analysis of randomized anti‐epileptic drug monotherapy trials. Journal of Evaluation in Clinical Practice2000;6(2):205‐14. ">Williamson 2000</a>). Furthermore, although most epilepsy monotherapy trials collect seizure data, there has been no uniformity in the definition and reporting of outcomes. For example, trials may report time to 12‐month remission but not time to first seizure or vice versa, or some trials may define time to first seizure from the date of randomisation while others use the date of achieving maintenance dose. Trial investigators have also adopted differing approaches to the analysis, particularly with respect to the censoring of time‐to‐event data. For these reasons, we performed this review using individual participant data (IPD), which helps to overcome these problems. This review is one in a series of Cochrane IPD reviews investigating pair‐wise monotherapy comparisons (<a href="./references#CD001031-bbs2-0056" title="MarsonAG , WilliamsonPR , HuttonJL , CloughHE , ChadwickDW . Carbamazepine versus valproate monotherapy for epilepsy. Cochrane Database of Systematic Reviews2000, Issue 3. [DOI: 10.1002/14651858.CD001030] ">Marson 2000</a>; <a href="./references#CD001031-bbs2-0062" title="NevittSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>; <a href="./references#CD001031-bbs2-0066" title="NolanSJ , MullerM , Tudur SmithC , MarsonAG . Oxcarbazepine versus phenytoin monotherapy for epilepsy. Cochrane Database of Systematic Reviews2013, Issue 5. [DOI: 10.1002/14651858.CD003615.pub3] ">Nolan 2013b</a>; <a href="./references#CD001031-bbs2-0067" title="NolanSJ , Tudur SmithC , PulmanJ , MarsonAG . Phenobarbitone versus phenytoin monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures. Cochrane Database of Systematic Reviews2013, Issue 1. [DOI: 10.1002/14651858.CD002217.pub2] ">Nolan 2013c</a>; <a href="./references#CD001031-bbs2-0068" title="NolanSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub3] ">Nolan 2016b</a>; <a href="./references#CD001031-bbs2-0069" title="NolanSJ , SudellM , Tudur SmithC , MarsonA . Topiramate versus carbamazepine monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD012065.pub2] ">Nolan 2016c</a>; <a href="./references#CD001031-bbs2-0070" title="NolanSJ , MarsonAG , PulmanJ , Tudur SmithC . Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD001769.pub3] ">Nolan 2016d</a>). These data have also been included in IPD network meta‐analyses of anti‐epileptic drug monotherapy (<a href="./references#CD001031-bbs2-0082" title="Tudur SmithC , MarsonAG , ChadwickDW , WilliamsonPR . Multiple treatment comparisons in epilepsy monotherapy trials. Trials2007;5(8):34. ">Tudur Smith 2007</a>; <a href="./references#CD001031-bbs2-0061" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonA . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>) </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD001031-sec-0035" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD001031-sec-0035"></div> <p>To review the time to treatment failure, remission and first seizure with lamotrigine compared to carbamazepine when used as monotherapy in people with focal onset seizures (simple or complex focal and secondarily generalised) or generalised onset tonic‐clonic seizures (with or without other generalised seizure types). </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD001031-sec-0036" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD001031-sec-0036"></div> <section id="CD001031-sec-0037"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD001031-sec-0038"> <h4 class="title">Types of studies</h4> <p> <ul id="CD001031-list-0001"> <li> <p>Randomised controlled trials (RCTs) using either an adequate method of allocation concealment (e.g. sealed, opaque envelopes) or a 'quasi' method of randomisation (e.g. allocation by date of birth). </p> </li> <li> <p>Trials may have been double‐blind, single‐blind or unblinded.</p> </li> <li> <p>Trials must have included a comparison of lamotrigine monotherapy with carbamazepine monotherapy in individuals with epilepsy. </p> </li> </ul> </p> </section> <section id="CD001031-sec-0039"> <h4 class="title">Types of participants</h4> <p> <ul id="CD001031-list-0002"> <li> <p>We included children or adults with focal onset seizures (simple focal, complex focal or secondarily generalised tonic‐clonic seizures) or generalised onset tonic‐clonic seizures, with or without other generalised seizure types (in other words, those who had only generalised tonic‐clonic seizures and those who had both generalised onset tonic‐clonic seizures and generalised seizures of other types (e.g. absence, myoclonic etc.)). </p> </li> <li> <p>We excluded individuals with other generalised seizure types alone without generalised tonic‐clonic seizures (e.g. those who had only absence seizures without any generalised clonic tonic‐seizures) due to differences in first‐line treatment guidelines for other generalised seizure types (<a href="./references#CD001031-bbs2-0064" title="National Institute for Health and Care Excellence. Clinical Guidance 137: The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: National Institute for Health and Care Excellence2012. ">NICE 2012</a>). </p> </li> <li> <p>We included individuals with a new diagnosis of epilepsy, or who have had a relapse following antiepileptic monotherapy withdrawal. </p> </li> </ul> </p> </section> <section id="CD001031-sec-0040"> <h4 class="title">Types of interventions</h4> <p>Carbamazepine or lamotrigine as monotherapy.</p> </section> <section id="CD001031-sec-0041"> <h4 class="title">Types of outcome measures</h4> <p>Below is a list of outcomes investigated in this review. Reporting of these outcomes in the original trial report was not an eligibility requirement for this review. </p> <section id="CD001031-sec-0042"> <h5 class="title">Primary outcomes</h5> <p>Time to treatment failure (retention time). This was a combined outcome reflecting both efficacy and tolerability, as the following may have lead to failure of treatment: continued seizures, side effects, non‐compliance or the initiation of additional add‐on treatment. This is an outcome to which the participant makes a contribution and is the primary outcome measure recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (<a href="./references#CD001031-bbs2-0045" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>; <a href="./references#CD001031-bbs2-0046" title="GlauserT , Ben‐MenachemE , BourgeoisB , CnaanA , ChadwickD , GuerreiroC , et al. ILAE treatment guidelines: evidence based analysis of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes. Epilepsia2006;47(7):1094‐120. ">ILAE 2006</a>). </p> <p>Time to treatment failure is considered according to three definitions:</p> <p> <ol id="CD001031-list-0003"> <li> <p>Time to treatment failure for any treatment related reason (continued seizures, side effects, non‐compliance or the initiation of additional add‐on treatment) </p> </li> <li> <p>Time to treatment failure due to adverse events (i.e. side effects)</p> </li> <li> <p>Time to treatment failure due to lack of efficacy (i.e. continued seizures)</p> </li> </ol> </p> </section> <section id="CD001031-sec-0043"> <h5 class="title">Secondary outcomes</h5> <p> <ul id="CD001031-list-0004"> <li> <p>Time to first seizure post randomisation.</p> </li> <li> <p>Time to achieve six‐month remission (seizure‐free period).</p> </li> <li> <p>Time to achieve 12‐month remission (seizure‐free period).</p> </li> <li> <p>Time to achieve 24‐month remission (seizure‐free period).</p> </li> <li> <p>Incidence of adverse events (all reported whether related or unrelated to treatment) and adverse events leading to treatment failure. </p> </li> </ul> </p> </section> </section> </section> <section id="CD001031-sec-0044"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD001031-sec-0045"> <h4 class="title">Electronic searches</h4> <p>The first searches for this review were run in 1997. Subsequent searches were run in July 2014, December 2015 and October 2016. For the most recent update we searched the following databases. </p> <p> <ul id="CD001031-list-0005"> <li> <p>Cochrane Epilepsy Group Specialized Register (26 February 2018) using the search strategy set out in <a href="./appendices#CD001031-sec-0111">Appendix 1</a>. </p> </li> <li> <p>Cochrane Central Register of Controlled Trials (CENTRAL) via the Cochrane Register of Studies Online (CRSO, 26 February 2018) using the search strategy set out in <a href="./appendices#CD001031-sec-0112">Appendix 2</a>. </p> </li> <li> <p>MEDLINE (Ovid, 1946 to 26 February 2018) using the search strategy set out in <a href="./appendices#CD001031-sec-0113">Appendix 3</a>. </p> </li> <li> <p><a href="https://clinicaltrials.gov/" target="_blank">ClinicalTrials.gov</a> (26 February 2018) using the search terms 'Lamotrigine AND carbamazepine | Epilepsy'. </p> </li> <li> <p><a href="http://apps.who.int/trialsearch/" target="_blank">WHO International Clinical Trials Registry Platform</a> (ICTRP, 26 February 2018) using the search terms ' Lamotrigine AND carbamazepine AND Epilepsy'. </p> </li> </ul> </p> <p>We imposed no language restrictions.</p> </section> <section id="CD001031-sec-0046"> <h4 class="title">Searching other resources</h4> <p>We reviewed the reference lists of retrieved studies to search for additional reports of relevant trials. We contacted Ciba Geigy (manufacturers of carbamazepine), GlaxoSmithKline (manufacturers of lamotrigine) and the original investigators of relevant trials identified by our search. </p> </section> </section> <section id="CD001031-sec-0047"> <h3 class="title" id="CD001031-sec-0047">Data collection and analysis</h3> <section id="CD001031-sec-0048"> <h4 class="title">Selection of studies</h4> <p>Two review authors (SJN and AGM) independently assessed trials for inclusion, resolving any disagreements by mutual discussion. </p> </section> <section id="CD001031-sec-0049"> <h4 class="title">Data extraction and management</h4> <p>We requested the following individual participant data for all trials meeting our inclusion criteria. </p> <section id="CD001031-sec-0050"> <h5 class="title">Trial methods</h5> <p> <ul id="CD001031-list-0006"> <li> <p>Method of generation of random list</p> </li> <li> <p>Method of concealment of randomisation</p> </li> <li> <p>Stratification factors</p> </li> <li> <p>Blinding methods</p> </li> </ul> </p> </section> <section id="CD001031-sec-0051"> <h5 class="title">Participant covariates</h5> <p> <ul id="CD001031-list-0007"> <li> <p>Gender</p> </li> <li> <p>Age</p> </li> <li> <p>Seizure types</p> </li> <li> <p>Time between first seizure and randomisation</p> </li> <li> <p>Number of seizures prior to randomisation (with dates)</p> </li> <li> <p>Presence of neurological signs</p> </li> <li> <p>Electroencephalographic (EEG) results</p> </li> <li> <p>Computerised tomography/magnetic resonance imaging (CT/MRI) results</p> </li> </ul> </p> </section> <section id="CD001031-sec-0052"> <h5 class="title">Follow‐up data</h5> <p> <ul id="CD001031-list-0008"> <li> <p>Treatment allocation</p> </li> <li> <p>Date of randomisation</p> </li> <li> <p>Dates of follow‐up</p> </li> <li> <p>Dates of seizures post randomisation or seizure frequency data between follow‐up visits</p> </li> <li> <p>Dates of treatment withdrawal or treatment failure and reasons for treatment withdrawal or treatment failure </p> </li> <li> <p>Dose</p> </li> <li> <p>Dates of dose changes</p> </li> </ul> </p> <p>For each trial for which we did not obtain individual participant data (IPD), we carried out an assessment to see whether any relevant aggregate level data had been reported or could be indirectly estimated using the methods of <a href="./references#CD001031-bbs2-0072" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>, and <a href="./references#CD001031-bbs2-0084" title="WilliamsonPR , Tudur SmithC , HuttonJL , MarsonAG . Aggregate data meta‐analysis with time‐to‐event outcomes. Statistics in Medicine2002;21(11):3337‐51. ">Williamson 2002</a>. Where graphical time‐to‐event data (e.g. Kaplan Meier curves) were published with or without corresponding effective numbers at risk, we used a Microsoft Excel spreadsheet (<a href="./references#CD001031-bbs2-0038" title="Microsoft . Microsoft Excel. Redmond, Washington: Microsoft, 2010. ">Excel 2010</a>), to indirectly estimate hazard ratios (<a href="./references#CD001031-bbs2-0081" title="TierneyJF , StewartLA , GhersiD , BurdettS , SydesMR . Practical methods for incorporating summary time‐to‐event data into meta‐analysis. Trials2007;8:16. ">Tierney 2007</a>). </p> <p>Four trials including 1391 participants provided seizure data in terms of the number of seizures recorded between each follow‐up visit rather than specific dates of seizures (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). To enable the calculation of time‐to‐event outcomes, we applied linear interpolation to approximate dates of seizures between follow‐up visits. For example, if the trial recorded four seizures between two visits that occurred on 1 March 2010 and 1 May 2010 (interval of 61 days), then the date of first seizure would be approximately 13 March 2010. This allowed the computation of an estimate of the time to six‐month remission, 12‐month remission, 24‐month remission and first seizure. </p> <p>We calculated time to six‐month, 12‐month and 24‐month remission from the date of randomisation to the date (or estimated date) that the individual had first been free of seizures for six, 12 or 24 months, respectively. If the person had one or more seizures during the trial, a six‐month, 12‐month or 24 month seizure‐free period could also occur between the estimated date of the last seizure during the trial and a period of six, 12 or 24 months of seizure freedom. </p> <p>We calculated time to first seizure from the date of randomisation to the date that we estimated their first seizure to have occurred. If seizure data were missing for a particular visit, we censored these outcomes at the previous visit. We also censored these outcomes if the individual died or if follow‐up ceased prior to the occurrence of the event of interest. We used these methods in five trials including 1383 participants (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>), for which we directly received outcome data (dates of seizures after randomisation). </p> <p>For all trials we received data for date and reason of withdrawal from the treatment or the date and reason for treatment failure. Time to treatment failure was calculated as date of randomisation to date of treatment failure. For the analysis of time‐to‐event, we defined an 'event' as treatment failure because of reasons related to the treatment (i.e. lack of efficacy, adverse events, or both lack of efficacy and adverse events, non‐compliance with the treatment regimen, withdrawal of consent from the trial, etc.). We censored the outcome if treatment failure or withdrawal of treatment was for reasons not related to the trial treatment: i.e. loss to follow‐up, death (not treatment or epilepsy‐related), treatment withdrawn due to remission, etc. We also censored individuals who were still on allocated treatment at the date of the end of follow‐up. We considered documented reasons for treatment failure or treatment withdrawal on a case‐by‐case basis for relation to treatment; two authors (SJN and AGM) independently classified reasons for treatment failure as events or censored and resolved any disagreements by discussion. If reasons for treatment failure were classified differently as events or censored in the included trials to our definitions, we conducted sensitivity analyses to account for differences in the definition of a treatment failure 'event' (see <a href="#CD001031-sec-0061">Sensitivity analysis</a>). </p> <p>For the analysis of 'Time to treatment failure due to adverse events,' only treatment failures which were documented to be due to adverse events (either as a sole reason or due to both a lack of efficacy and adverse events) were classed as an 'event' within time‐to‐event analyses and all other reasons for treatment failure were censored. Similarly, for the analysis of 'Time to treatment failure due to lack of efficacy' only treatment failures which were documented to be due to lack of efficacy (i.e. continued seizures, either as a sole reason or due to both a lack of efficacy and adverse events) were classed as an 'event' within time‐to‐event analyses and all other reasons for treatment failure were censored. </p> </section> </section> <section id="CD001031-sec-0053"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>Two review authors (SJN and JW) independently assessed the risk of bias for each trial using the Cochrane 'Risk of bias' tool, as described in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001031-bbs2-0043" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). We rated each of the following six domains as low, unclear or high risk of bias: method of generating random sequence, allocation concealment, blinding methods, incomplete outcome data, selective outcome reporting and other sources of bias. Any discrepancies in risk of bias judgements of the two review authors were resolved by discussion. In the event of the presence of high risk of bias in included trials (due to inadequate allocation concealment or lack of blinding), we planned sensitivity analyses excluding these trials. </p> </section> <section id="CD001031-sec-0054"> <h4 class="title">Measures of treatment effect</h4> <p>We measured all outcomes in this review as time‐to‐event outcomes with the hazard ratio (HR) and 95% confidence interval (CI) used as the measure of treatment effect. We calculated outcomes from IPD provided, where possible, or extracted from published trials if possible. </p> </section> <section id="CD001031-sec-0055"> <h4 class="title">Unit of analysis issues</h4> <p>The unit of allocation and analysis was the individual for all included trials; and no trials included in meta‐analyses were of a repeated measures (longitudinal) nature or of a cross‐over design. </p> <p>One included trial allocated participants to three treatment arms, 100 mg/day lamotrigine, 200 mg/day lamotrigine or 600 mg/day carbamazepine (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). In the primary analysis for all outcomes, we pooled the two lamotrigine arms and calculated a hazard ratio of lamotrigine compared to carbamazepine using the IPD provided. In sensitivity analysis, we calculated separate hazard ratios for 100 mg/day lamotrigine versus carbamazepine and 200 mg/day lamotrigine versus carbamazepine to examine any difference in the doses of lamotrigine compared to carbamazepine. </p> </section> <section id="CD001031-sec-0056"> <h4 class="title">Dealing with missing data</h4> <p>For each trial that supplied IPD, we reproduced results from trial results where possible and performed the following consistency checks. </p> <p> <ul id="CD001031-list-0009"> <li> <p>We cross‐checked trial details against any published report of the trial and contacted original trial authors if we found missing data, errors or inconsistencies. If trial authors could not resolve inconsistencies between the IPD and the published data, depending on the extent of the inconsistencies, we performed sensitivity analysis or excluded the data from the meta‐analysis. </p> </li> <li> <p>We reviewed the chronological randomisation sequence and checked the balance of prognostic factors, taking account of factors stratified for in the randomisation procedure. </p> </li> </ul> </p> </section> <section id="CD001031-sec-0057"> <h4 class="title">Assessment of heterogeneity</h4> <p>We assessed heterogeneity statistically using the Q test (P value less than 0.10 for significance) and the I² statistic (<a href="./references#CD001031-bbs2-0041" title="HigginsJPT , ThompsonSG , DeeksJJ , AltmanDG . Measuring inconsistency in meta‐analyses. BMJ2003;327:557‐60. ">Higgins 2003</a>) (greater than 50% indicating considerable heterogeneity), with output produced using the generic inverse variance approach outlined in <a href="./references#CD001031-sec-0109" title="">Data and analyses</a>, and visually by inspecting forest plots. </p> </section> <section id="CD001031-sec-0058"> <h4 class="title">Assessment of reporting biases</h4> <p>Two review authors (SJN and JW) undertook all full quality and 'Risk of bias' assessments according to the methods outlined in the <i>Cochrane Handbook for Systematic Reviews of Interventions</i> (<a href="./references#CD001031-bbs2-0043" title="HigginsJPT , AltmanDG , Sterne JAC(editors) . Chapter 8: Assessing risk of bias in included studies. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). Available from handbook.cochrane.org. The Cochrane Collaboration, 2011. ">Higgins 2011</a>). In theory, a review using IPD should overcome issues of reporting biases as unpublished data can be provided and unpublished outcomes calculated. We requested trial protocols with IPD for all trials. Any selective reporting bias detected could be assessed with the Outcome Reporting Bias In Trials (ORBIT) classification system (<a href="./references#CD001031-bbs2-0048" title="KirkhamJJ , DwanKM , AltmanDG , GambleC , DoddS , SmythR , et al. The impact of outcome reporting bias in randomised controlled trials on a cohort of systematic reviews. BMJ2010;340:c365. ">Kirkham 2010</a>). </p> </section> <section id="CD001031-sec-0059"> <h4 class="title">Data synthesis</h4> <p>We carried out our analysis on an intention‐to‐treat basis (that is, we analysed participants in the group to which they were randomised, irrespective of which treatment they actually received). Therefore, for the time‐to‐event outcomes, 'time to six‐month remission', 'time to 12‐month remission', 'time to 24 month remission' and 'time to first seizure post randomisation', we did not censor participants if treatment was withdrawn or if treatment failure occurred but follow‐up within the trial continued (e.g. if a participant continued to be followed up on a different treatment). </p> <p>An intention‐to‐treat analysis tends toward finding no difference between treatments and we would have undertaken a secondary 'protocol correct' analysis as a sensitivity analysis if the primary analyses had suggested equivalence, in which case participants would have been censored at the time of treatment failure for seizure outcomes. </p> <p>For all outcomes, we investigated the relationship between the time‐to‐event and treatment effect of the AEDs. We used Cox proportional hazards regression models to obtain trial‐specific estimates of log (hazard ratio) or treatment effect and associated standard errors in Stata Statistical Software, version 14 (<a href="./references#CD001031-bbs2-0080" title="StataCorp . Stata Statistical Software: Release 14. CollegeStation, TX: StataCorp LP, 2015. ">Stata 2015</a>). The model assumes that the ratio of hazards (risks) between the two treatment groups is constant over time (i.e. hazards are proportional). We tested this proportional hazards assumption of the Cox regression model for each outcome of each trial by testing the statistical significance of a time varying covariate in the model. We evaluated overall pooled estimates of hazard ratios (with 95% confidence intervals) using the generic inverse variance method. We expressed results as a hazard ratio (HR) and a 95% confidence interval (CI). </p> <p>By convention, a HR greater than 1 indicates that an event is more likely to occur earlier on lamotrigine than on carbamazepine. Hence, for time to treatment failure or time to first seizure, a HR greater than 1 indicates a clinical advantage for carbamazepine (e.g. a HR of 1.2 would suggest a 20% increase in hazard of treatment failure from lamotrigine compared with carbamazepine), and for time to six‐month, 12‐month and 24‐month remission a HR greater than 1 indicates a clinical advantage for lamotrigine (i.e. the seizure‐free period occurs earlier on lamotrigine than carbamazepine). </p> </section> <section id="CD001031-sec-0060"> <h4 class="title">Subgroup analysis and investigation of heterogeneity</h4> <p>There is a strong clinical belief that some AEDs are more effective in some seizure types than others (see <a href="#CD001031-sec-0032">Description of the intervention</a> and <a href="#CD001031-sec-0033">How the intervention might work</a>), therefore we stratified all analyses by seizure type (focal onset versus generalised onset), according to the classification of main seizure type at baseline. We classified focal seizures (simple or complex) and focal secondarily generalised seizures as focal epilepsy. We classified primarily generalised seizures as generalised epilepsy. </p> <p>We conducted a Chi² test of interaction between treatment and epilepsy type. If we found significant statistical heterogeneity to be present, we performed meta‐analysis with a random‐effects model in addition to a fixed‐effect model, presenting the results of both models and performing sensitivity analyses to investigate differences in trial characteristics. If heterogeneity is found to be present in future updates and available data allow, we may investigate variables that may contribute to the variability (e.g. participant covariates, trial design) via regression models </p> </section> <section id="CD001031-sec-0061"> <h4 class="title">Sensitivity analysis</h4> <p>We performed several sensitivity analyses to test the robustness of our results to characteristics of the included trials, as follows. </p> <p> <ul id="CD001031-list-0010"> <li> <p>Definition of time to treatment failure: we classified reasons for treatment failure that were related to the trial treatment as 'events' and 'censored' reasons not related to treatment in the analysis of 'time to treatment failure'. If reasons for treatment failure were classified differently as events or censored in included trials to our definitions, we conducted sensitivity analyses to account for differences in the definition of a treatment failure 'event'. </p> </li> </ul> </p> <p>One trial considered participants to have completed the trial and hence withdrew treatment if they experienced a seizure after week six (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). This does not correspond with the treatment failure definition recommended by <a href="./references#CD001031-bbs2-0045" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>, and used in this review. We included treatment failure data for the participants from this study, <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, in the primary analysis of time to treatment failure and excluded them in sensitivity analysis to examine any effect of the difference in definition of treatment failure. </p> <p> <ul id="CD001031-list-0011"> <li> <p>Seizure dates: one trial did not include seizures that occurred during the first four weeks of the trial in efficacy analyses and dates of seizures before week four were not supplied to us (<a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>). Therefore, we calculated seizure outcomes as the time to first seizure and time to six‐month remission after week four rather than after randomisation. We included seizure data from this study in the primary analysis of time to first seizure and time to six‐month remission and excluded them in sensitivity analysis to examine any effect of the difference in origin time of the seizure count. </p> </li> </ul> <ul id="CD001031-list-0012"> <li> <p>Aggregate data: time to treatment failure was presented as summary statistics or graphically in four of the trials for which IPD were not available (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>) and time to first seizure was presented graphically in three of the trials for which IPD were not available (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). In <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>, hazard ratios and 95% confidence intervals were published for both time‐to‐event outcomes. Due to the small number of events for the outcomes in two studies (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>), it was possible to estimate individual treatment failure/seizure times from the graphs and therefore calculate an estimated hazard ratio. In <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, we used indirect methods and approximate numbers at risk at a range of time points throughout the trials (described in <a href="#CD001031-sec-0049">Data extraction and management</a>) to estimate the hazard ratios for the outcomes. These estimated hazard ratios are combined with the hazard ratios calculated from the trials providing IPD in sensitivity analysis. </p> </li> </ul> <ul id="CD001031-list-0013"> <li> <p>Seizure freedom: all included trials were of at least 24 weeks' (around six months') duration. Those providing IPD that were over six months' duration contributed to the outcome 'time to six‐month remission of seizures' (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Two trials were of 24 weeks' duration (<a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>). </p> </li> </ul> </p> <p>We conducted sensitivity analysis calculating a pooled risk ratio of seizure freedom at six months and including the data from two studies (<a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>), (assuming 24 weeks is approximately equal to six months) and the trials for which IPD were not available. We estimated seizure freedom at six months from the graph of time to first seizure published in <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>. We also conducted sensitivity analysis, calculating a pooled risk ratio of seizure freedom throughout the whole trial combining IPD and aggregated data from all included trials. </p> <p> <ul id="CD001031-list-0014"> <li> <p>Misclassification of seizure type is a recognised problem in epilepsy, whereby some people with generalised seizures have been mistakenly classed as having focal onset seizures and vice versa. There is clinical evidence that individuals with generalised onset seizures are unlikely to have an 'age of onset' greater than 25 to 30 years (<a href="./references#CD001031-bbs2-0055" title="MalafosseA , GentonP , HirschE , MarescauxC , BroglinD , BernasconiR . Idiopathic Generalised Epilepsies: Clinical, Experimental and Genetic. Eastleigh: John Libbey and Company, 1994. ">Malafosse 1994</a>). Such misclassification impacted upon the results of three reviews in our series of pair‐wise reviews for monotherapy in epilepsy comparing carbamazepine, phenobarbitone, phenytoin and sodium valproate in which around 30% to 50% of participants analysed may have had their seizure type misclassified as generalised onset (<a href="./references#CD001031-bbs2-0070" title="NolanSJ , MarsonAG , PulmanJ , Tudur SmithC . Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD001769.pub3] ">Nolan 2016d</a>; <a href="./references#CD001031-bbs2-0068" title="NolanSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub3] ">Nolan 2016b</a>; <a href="./references#CD001031-bbs2-0062" title="NevittSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>). Given the potential biases introduced into those reviews, we examined the distribution of age at onset for individuals with generalised seizures in the trials included in this review, to assess the potential impact of misclassification of seizure type on the outcomes. </p> </li> </ul> </p> <p>Two trials recruited only individuals with focal onset seizures (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), therefore there were no participants with new onset generalised seizures over the age of 30 in these trials. </p> <p>Two trials were designed to include participants with focal onset seizures only, however three participants in <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, and nine participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, were classified as having generalised onset seizures. Further, seizure type was missing for 85 participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>. We considered the individuals in these two trials to have a misclassification of seizure type. Overall: </p> <p> <ul id="CD001031-list-0015"> <li> <p>in <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>, 20 out of the 54 participants (37%) classified as having generalised onset seizures were over the age of 30 at entry into the trial (and all over the age of 29 at seizure onset); </p> </li> <li> <p>in <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>, 23 out of the 62 participants (37%) classified as having generalised onset seizures were over the age of 30 at entry into the trial (and all over the age of 29 at seizure onset); </p> </li> <li> <p>in <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>, all 45 of the participants (100%) classified as having generalised onset seizures were over the age of 30 at entry into the trial (no age of onset data provided); </p> </li> <li> <p>in <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>, 9 out of the 15 participants (60%) classified as having generalised onset seizures were over the age of 30 at entry into the trial (no age of onset data provided); </p> </li> <li> <p>in <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, 43 out of the 114 participants (38%) classified as having generalised onset seizures were over the age of 30 at entry into the trial (and all over the age of 23 at seizure onset). </p> </li> </ul> </p> <p>In total, 152 out of 302 participants (50%) classified as having generalised onset seizures may have been wrongly classified as having new onset generalised seizures. To investigate misclassification for each outcome, we undertook two sensitivity analyses: </p> <p> <ul id="CD001031-list-0016"> <li> <p>we reclassified the 152 individuals with generalised seizure types and age at onset greater than 30 as having focal onset seizures and repeated subgroup analysis; </p> </li> <li> <p>for <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, we reclassified the 152 individuals with generalised seizure types and age at onset greater than 30, and the 85 individuals with missing seizure type, into an 'uncertain seizure type' group and repeated subgroup analysis with three groups. </p> </li> </ul> </p> <section id="CD001031-sec-0062"> <h5 class="title">Summary of findings and quality of the evidence (GRADE)</h5> <p>For the 2016 update, in a post hoc change from protocol, we have added two 'Summary of findings' tables to the review (outcomes in the tables decided before the update started based on clinical relevance). </p> <p><a href="./full#CD001031-tbl-0001">summary of findings Table for the main comparison</a> reports the primary outcome of 'time to treatment failure' in the subgroups of participants with focal onset seizures, generalised onset seizures and overall adjusted by epilepsy type. </p> <p><a href="./full#CD001031-tbl-0002">summary of findings Table 2</a> reports the secondary outcomes of 'time to first seizure' and 'time to 12‐month remission' in the subgroups of participants with focal onset seizures, generalised onset seizures and overall adjusted by epilepsy type. (Due to small numbers of participants with generalised seizures contributing to the outcome of time to 12‐month remission, an overall treatment effect for all participants is presented in <a href="./full#CD001031-tbl-0002">summary of findings Table 2</a>.) </p> <p>We determined the quality of the evidence using the GRADE approach, where we downgraded evidence in the presence of high risk of bias in at least one trial, indirectness of the evidence, unexplained heterogeneity or inconsistency, imprecision of results and high probability of publication bias. We downgraded evidence by one level if the limitation was considered serious and two levels if considered very serious, as judged by the review authors. Under the GRADE approach, evidence may also be upgraded if a large treatment effect is demonstrated with no obvious biases or if a dose‐response effect exists. </p> </section> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD001031-sec-0063" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD001031-sec-0063"></div> <section id="CD001031-sec-0064"> <h3 class="title">Description of studies</h3> <section id="CD001031-sec-0065"> <h4 class="title">Results of the search</h4> <p>We included five trials in previous versions of this review (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). </p> <p>For the 2016 update of this review, we identified 148 records from the databases and search strategies outlined in <a href="#CD001031-sec-0045">Electronic searches</a>. We removed 40 duplicate records and screened the titles and abstracts of 108 records for inclusion in the review. We excluded 81 records based on the title and abstract and assessed 27 full‐text articles for inclusion in the review. We excluded 18 articles from the review (see <a href="#CD001031-sec-0067">Excluded studies</a> below), classified one article as awaiting assessment (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>) and included eight additional trials (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). </p> <p>For the 2018 update of this review, we identified 52 records from the databases and search strategies outlined in <a href="#CD001031-sec-0045">Electronic searches</a>. We removed 17 duplicate records and screened the titles and abstracts of 35 records for inclusion in the review. All 35 records were clearly irrelevant and were excluded. The one article which was classified as awaiting in assessment in the 2016 update of the review was now included (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>). Therefore, we included a total of 14 studies were included in the review (see <a href="#CD001031-sec-0066">Included studies</a>). </p> <p>See <a href="#CD001031-fig-0001">Figure 1</a> for a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) study flow diagram. </p> <div class="figure" id="CD001031-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Study flow diagram." data-id="CD001031-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> </div> </section> <section id="CD001031-sec-0066"> <h4 class="title">Included studies</h4> <p>We identified 13 published reports that met the inclusion criteria for this review (<a href="./references#CD001031-bbs2-0034" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. ">Brodie 1995</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). One of the published reports (<a href="./references#CD001031-bbs2-0034" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. ">Brodie 1995</a>), contained results on two separate randomised controlled trials run on very similar protocols (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>). Although the two trials were reported within the same publication we treated them as separate trials within this Cochrane Review; therefore we included a total of 14 trials in the review. </p> <p>One trial recruited adults of all ages (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>), and one trial recruited adults over the age of 16 (<a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>). One trial recruited children between the ages of 6 and 12 (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>). Two trials recruited individuals over the age of 12 (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>), and two recruited individuals over the age of 13 (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>). One trial recruited individuals over the age of two (<a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>), and one recruited individuals over the age of four (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Four trials recruited the elderly; two trials recruited individuals over the age of 60 (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), and two recruited individuals over the age of 65 (<a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). The remaining trial did not state the eligible age ranges recruited (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>). </p> <p>Five trials were designed to recruit individuals with focal seizures only (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>); however three of these trials did recruit some individuals with generalised onset seizures (<a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). We examine this seizure classification in sensitivity analysis. The remaining nine trials recruited individuals with focal or generalised tonic‐clonic seizures with or without other generalised seizure types. </p> <p>Seven trials recruited individuals with new onset seizures (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Four trials recruited individuals with new onset or untreated seizures (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>), one trial recruited individuals with new onset, untreated or seizures treated to a “sub‐therapeutic” level (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>), one trial recruited individuals with new onset, relapsed or recurrent seizures (failure of an AED not randomised in the trial) (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), and one trial recruited individuals with new onset seizures following ischaemic stroke (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>). </p> <p>Four multicentre trials were conducted in the UK (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Two multicentre trials were conducted across Europe (<a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), one multicentre trial across Europe and Mexico (<a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>), and one multicentre trial across Europe and Australia (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). One multicentre trial was conducted in Germany (<a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>), one multicentre trial in the USA (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>), three multicentre trials in the Republic of Korea (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>), and one single‐centre trial was conducted in Israel (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>). </p> <p>We did not obtain individual participant data (IPD) for five trials including a total of 1215 participants. According to trial sponsor, GlaxoSmithKline, data could not be located for two trials (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>), and data could not be provided due to restrictions over the anonymisation of datasets of trials conducted in Germany (<a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>). For the other two trials, we made contact with the authors/sponsors who expressed interest in collaborating in this IPD meta‐analysis but at the time of writing, no data had been received (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>). If IPD are received from these trials, we will include the data in future updates. </p> <p>Individual participant data were available for the remaining nine trials, which recruited a total of 2572 participants, representing 68% of 3787 individuals from all 14 identified eligible trials. Data were available for the following participant characteristics (percentage of 2572 participants with data available): drug randomised (100%), sex (99%, data missing for 18 participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), seizure type (97%, data missing for 85 participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), age at randomisation (99%, data missing for 18 participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, one participant in <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, and two participants in <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>), and number of seizures in the six months prior to randomisation (99%, missing for 18 participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, one participant in <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, and six participants in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Time since first seizure to randomisation was provided for 691 participants out of 695 participants from four trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> (data missing for one participant); <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> (data missing for three participants)). </p> <p>Seven trials provided the results of neurological examinations for 1693 out of 1711 participants (99%) (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> (data for 18 participants missing)). </p> <p>Six trials provided electroencephalographic (EEG) results for 710 out of 1044 participants (64%) (134 from <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>, 118 from <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>, 84 from <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>, 110 from <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>, 26 from <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, and 238 from <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). </p> <p>Seven trials provided computerised tomography/magnetic resonance imaging (CT/MRI) results for 788 out of 1194 participants (66%) (94 from <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>, 92 from <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>, 149 from <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>, 84 from <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>, 110 from <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>, 21 from <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, and 238 from <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). </p> <p>See the <a href="./references#CD001031-sec-0124" title="">Characteristics of included studies</a> table, <a href="#CD001031-tbl-0003">Table 1</a> and <a href="#CD001031-tbl-0004">Table 2</a> for further details. </p> <div class="table" id="CD001031-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Focal seizures: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Male gender: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Age at entry (years):</b> </p> <p><b>Mean (SD), range</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Aged &gt; 30 and generalised seizures: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Epilepsy duration (years):</b> </p> <p><b>Mean (SD), range</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of seizures in prior</b> </p> <p><b>6 months: median (range)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (63%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (58%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (42%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.3 (17.1), 15 to 71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 (14.4), 13 to 69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (3.3), 0 to 17.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8 (2.3), 0.3 to 11.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1 to 490)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 960)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (44%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (43%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (48%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.9 (14.5), 14 to 86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.1 (13.9), 14 to 81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (3.2), 0 to 19.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (1.8), 0 to 7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 1020)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 122)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (71%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (69%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (54%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (58%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3 (6.1), 65 to 94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2 (5.9), 66 to 88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (1 to 108)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (59%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 (2.0), 6 to 13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (2.1), 5 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 (0.9), 0 to 4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.3), 0 to 1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3(2 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (83%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (42%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (62%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.6 (12.6), 16 to 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (11.5), 16 to 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(0 to 60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0 to 200)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (99.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 (99.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222 (53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 (53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.1 (21.7), 2 to 84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.5 (21.0), 2 to 77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1 to 9000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 3600)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 (65%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (72%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (50%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.8 (14.0), 12 to 71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7 (14.6), 13 to 71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (3.2), 0 to 17.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (3.7), 0.26 to 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3(1 to 133)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 145)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205 (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.8 (18.4), 6 to 83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (18.4), 5 to 82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>727</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(0 to 1185)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (0 to 466)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (59%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (54%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8 (7.5), 60 to 88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.8 (6.7), 60 to 89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CBZ = carbamazepine, LTG = lamotrigine; n = number of participants; NA = not applicable; SD = standard deviation </p> </div> </div> <div class="table" id="CD001031-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline neurologic characteristics of participants (trials providing individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>EEG normal: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>CT scan normal: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Neurological exam</b> </p> <p><b>normal: n (%)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (46%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (46%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (84%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (90%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (73%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (79%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (83%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (39%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (48%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (58%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (65%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (88%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37(90%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (98%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (54%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (51%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (63%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (72%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (44%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (73%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (83%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 (89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (85%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>756</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>756</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (75%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281 (76%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (38%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (31%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (22%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (21%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CBZ = carbamazepine; CT = computerised tomography; EEG = electroencephalogram; LTG = lamotrigine; n = number of participants; NA = not applicable </p> </div> </div> </section> <section id="CD001031-sec-0067"> <h4 class="title">Excluded studies</h4> <p>We excluded seven duplicate references (<a href="./references#CD001031-bbs2-0018" title="EunS , EunB , LeeJ , LeeY , HwangY , KimK , et al. The effects of cognition and behavior of lamotrigine compared to carbamazepine as monotherapy for children with partial epilepsy. Epilepsia2008;49(Suppl 7):87, Abstract No: 1.200. ">Eun 2008</a>; <a href="./references#CD001031-bbs2-0022" title="LeeS‐A , LeeH‐W , HeoK , SongH‐K , KimO‐J , LeeS‐M , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Epilepsia2010;51(Suppl 4):116, Abstract no: p393. ">Lee 2010</a>; <a href="./references#CD001031-bbs2-0025" title="RamsayRE , RowanAJ , PryorFM , CollinsJF , DVA Coop Study Group 428. Treatment of seizures in the elderly: final analysis from DVA Cooperative Study. Epilepsia2003;44 (Suppl 9):170. ">Ramsay 2003</a>; <a href="./references#CD001031-bbs2-0026" title="SaetreE , PeruccaE , IsojärviJ , GjerstadL . An international multicenter double‐blind double‐dummy randomised trial comparing lamotrigine and slow‐release carbamazepine for treating newly diagnosed epilepsy in the elderly. Epilepsia. 7th European Congress on Epileptology, Helsinki, Finland. 2‐6 July 2006, 2006; Vol. 47:1. ">Saetre 2006</a>; <a href="./references#CD001031-bbs2-0027" title="SaetreE , AbdelnoorM , AmlieJP , TossebroM , PeruccaE , TaubollE , et al. Cardiac function and antiepileptic drug treatment in the elderly: a comparison between lamotrigine and sustained‐release carbamazepine. Epilepsia2009;50(8):1841‐9. ">Saetre 2009</a>; <a href="./references#CD001031-bbs2-0028" title="SaetreE , AbdelnoorM , PeruccaE , TaubollE , IsojarviJ , GjerstadL . Antiepileptic drugs and quality of life in the elderly: results from a randomized double‐blind trial of carbamazepine and lamotrigine in patients with onset of epilepsy in old age. Epilepsy and Behaviour2010;17(3):395‐401. ">Saetre 2010</a>; <a href="./references#CD001031-bbs2-0030" title="SteinhoffBJ , UeberallMA , SiemesH , BergmannL . The lam‐safe study: lamotrigine versus carbamazepine and valproic acid in newly diagnosed focal and generalized epilepsies in adolescents and adults. Epilepsia2004;45 (Suppl 3):68, Abstract no: 055. ">Steinhoff 2004</a>), and retained the most relevant primary reference for the trial in the review (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>, respectively). We excluded five trials that did not compare lamotrigine and carbamazepine (<a href="./references#CD001031-bbs2-0017" title="CzapinskiP , TerczynskiA , CzapinskaE . Open randomised comparative study of vigabatrin (VGB) and lamotrigine (LTG) efficacy in monotherapy of patients with drug‐resistant epilepsy with partial complex seizures resistant to carbamazepine. Epilepsia. 1997; Vol. 38 (Suppl 3):35. CzapinskiP , TerczynskiA , CzapinskaE . Open randomized comparative study of vigabatrin (VGB) and lamotrigine (LTG) efficacy in monotherapy of patients with drug‐resistant epilepsy with partial complex seizures resistant to carbamazepine (CBZ). Journal of the Neurological Sciences1997;150 (Suppl):S96. CzapinskiP , TerczynskiA , CzapiskaE . Open randomized comparative study of vigabatrin (VGB) and lamotrigine (LTG) efficacy in monotherapy of patients with drug‐resistant epilepsy with partial complex seizures resistant to carbamazepine (CBZ). Journal of Neurology. 1997; Vol. 244 (Suppl 3):S34. ">Czapinski 1997</a>; <a href="./references#CD001031-bbs2-0020" title="GilliamF , VazquezB , SackellaresJC , ChangGY , MessenheimerJ , NybergJ , et al. An active‐control trial of lamotrigine monotherapy for partial seizures. Neurology1998;51(4):1018‐25. ">Gilliam 1998</a>; <a href="./references#CD001031-bbs2-0024" title="MotteJ , TrevathanE , ArvidssonJFV , BarreraMN , MullensEL , ManascoP . Lamotrigine for generalized seizures associated with the Lennox‐Gastaut syndrome. New England Journal of Medicine1997;337(25):1807‐12. ">Motte 1997</a>; <a href="./references#CD001031-bbs2-0029" title="SteinerTJ , DellaportasCI , FindleyLJ , GrossM , GibberdFB , PerkinGD , et al. Lamotrigine monotherapy in newly diagnosed untreated epilepsy; a double‐blind comparison with phenytoin. Epilepsia1999;40(5):601‐7. ">Steiner 1999</a>; <a href="./references#CD001031-bbs2-0031" title="StolarekI , BlacklawJ , ForrestG , BrodieMJ . Vigabatrin and lamotrigine in refractory epilepsy. Journal of Neurology, Neurosurgery, and Psychiatry1994;57(8):921‐4. ">Stolarek 1994</a>). We excluded three trials that were not of a monotherapy design (<a href="./references#CD001031-bbs2-0016" title="CarmantL , CurtisP , MooratAM . Switching paediatric patients to monotherapy: efficacy and tolerability for lamotrigine compared with carbamazepine. Epilepsia2001;42 (Suppl 7):170. ">Carmant 2001</a>; <a href="./references#CD001031-bbs2-0019" title="FakhouryT , GazdaS , NanryKP , HammerAE , BarrettPS . Comparison of monotherapy with lamotrigine versus carbamazepine in patients with uncontrolled epilepsy with a broad spectrum of seizure types. Epilepsia2000;41 (Suppl 7):107. ">Fakhoury 2000</a>; <a href="./references#CD001031-bbs2-0021" title="JawadS , RichensA , GoodwinG , YuenWC . Controlled trial of lamotrigine (Lamictal) for refractory partial seizures. Epilepsia1989;30(3):356‐63. ">Jawad 1989</a>). We excluded two trials that were not randomised (<a href="./references#CD001031-bbs2-0023" title="MartinezW , KaminowL , NanryKP , HammerAE , BarrettPS . Evaluation of lamotrigine versus carbamazepine, phenytoin, or divalproex sodium as monotherapy for epilepsy patients who failed or could not tolerate previous antiepileptic drug therapy. Epilepsia2000;41 (Suppl 7):100, Abstract no: 2.044. NanryKP , MartinezW , LiH , HammerAE , BarrettPS . Epilepsy patients switched from older antiepileptic drugs to lamotrigine monotherapy show improvement in quality of life. Epilepsia2000;41 (Suppl 7):176, Abstract no: 3.013. ">Martinez 2000</a>; <a href="./references#CD001031-bbs2-0032" title="ZengK , WangX , XiZ , YanY . Adverse effects of carbamazepine, phenytoin, valproate and lamotrigine monotherapy in epileptic adult Chinese patients. Clinical Neurology &amp; Neurosurgery2010;112(4):291‐5. ">Zeng 2010</a>). We excluded one trial that did not make a fully randomised comparison of lamotrigine and carbamazepine (<a href="./references#CD001031-bbs2-0015" title="BaxterL , CheesbroughA . An open randomised comparison of Lamictal (Lamotrigine) with physicians preferred choice of either valproate or carbamazepine as monotherapy in patients over 12 years of age with newly diagnosed epilepsy. Clinical Summary ReportMay 1998. ">Baxter 1998</a>); lamotrigine was compared to the treating physician's choice of carbamazepine or sodium valproate. See <a href="./references#CD001031-sec-0125" title="">Characteristics of excluded studies</a> for further details. </p> </section> </section> <section id="CD001031-sec-0068"> <h3 class="title">Risk of bias in included studies</h3> <p>For further details, see the <a href="./references#CD001031-sec-0124" title="">Characteristics of included studies</a> table and <a href="#CD001031-fig-0002">Figure 2</a>. </p> <div class="figure" id="CD001031-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001031-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG02.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> </div> <section id="CD001031-sec-0069"> <h4 class="title">Allocation</h4> <section id="CD001031-sec-0070"> <h5 class="title">(1) Trials for which we received individual participant data (information reported in published papers or provided with IPD) </h5> <p>All nine trials used adequate methods of randomisation via computer‐generated random list and we judged them to be at low risk of bias (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>); two trials reported that block randomisation was used (<a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), and one trial reported that minimisation was used (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). </p> <p>Seven trials reported adequate methods of allocation concealment and we judged them to be at low risk of bias; five concealed treatment allocation with sealed, opaque envelopes (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>); one trial used telephone randomisation to a central allocation service (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), and one trial used pharmacy allocation (<a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). The remaining two trials did not report how allocation was concealed and we judged them to be at unclear risk of bias (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>). </p> </section> <section id="CD001031-sec-0071"> <h5 class="title">(2) Trials for which no individual participant data were available (information reported in published papers only) </h5> <p>One of the trials reported that blocked randomisation via a computer‐generated list and telephone randomisation to a central allocation service were used (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>). We judged this trial to be at low risk of selection bias for random sequence generation and allocation concealment. The remaining four trials were described as "randomised" but did not provide information about the method of generation of the random list or allocation concealment so we judged them to be at unclear risk of bias (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>). </p> </section> </section> <section id="CD001031-sec-0072"> <h4 class="title">Blinding</h4> <section id="CD001031-sec-0073"> <h5 class="title">(1) Trials for which we received individual participant data (information reported in published papers or provided with IPD) </h5> <p>Four trials were double‐blind (participants and personnel) with the blinding achieved by using tablets of identical appearance; we judged these trials to be at low risk of performance bias (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). In all four of these trials, the trial investigator was blinded but no information was provided as to whether other outcome assessors were blinded, therefore we judged all four trials to be at unclear risk of detection bias. </p> <p>The remaining five trials were open‐label and we judged them to be at high risk of performance and detection bias (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). </p> </section> <section id="CD001031-sec-0074"> <h5 class="title">(2) Trials for which no individual participant data were available (information reported in published papers only) </h5> <p>Two trials were double‐blind (participants and personnel) with the blinding achieved by using double dummy tablets; we judged these trials to be at low risk of performance bias (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). However, for these two trials no information was provided regarding blinding of outcome assessors therefore we judged the two trials to be at unclear risk of detection bias. </p> <p>The remaining three trials were open‐label and we judged them to be at high risk of performance and detection bias (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>). </p> </section> </section> <section id="CD001031-sec-0075"> <h4 class="title">Incomplete outcome data</h4> <section id="CD001031-sec-0076"> <h5 class="title">(1) Trials for which we received individual participant data (information reported in published papers or provided with IPD) </h5> <p>In theory, a review using individual participant data should overcome issues of attrition bias as unpublished data can be provided, unpublished outcomes calculated and all randomised participants can be analysed by an intention‐to‐treat approach. All nine trials provided individual participant data for all randomised individuals and reported the extent of follow‐up for each individual (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). We queried any missing data with the original trial authors. From the information provided by the authors, we deemed the small amount of missing data present (see <a href="#CD001031-sec-0066">Included studies</a>) to be missing at random and not effecting our analysis. </p> </section> <section id="CD001031-sec-0077"> <h5 class="title">(2) Trials for which no individual participant data were available (information reported in published papers only) </h5> <p>Three trials reported attrition rates and analysed all randomised participants using an intention‐to‐treat approach and we judged them to be at low risk of attrition bias (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). The remaining two trials did not analyse data for all randomised participants (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>) and one of the trials did not state to which drug those excluded from analysis were randomised (<a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>). This is not an intention‐to‐treat analysis therefore we judged these trials to be at high risk of attrition bias. </p> </section> </section> <section id="CD001031-sec-0078"> <h4 class="title">Selective reporting</h4> <section id="CD001031-sec-0079"> <h5 class="title">(1) Trials for which we received individual participant data (information reported in published papers or provided with IPD) </h5> <p>In theory, a review using individual participant data should overcome issues of reporting biases as unpublished data can be provided and unpublished outcomes calculated. We sought trial protocols in all individual participant data requests and seven protocols were provided (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). We received sufficient individual participant data to calculate all outcomes for all nine trials (depending on trial duration; e.g. time to 12‐month remission could not be calculated for a trial of 24 weeks etc.) </p> </section> <section id="CD001031-sec-0080"> <h5 class="title">(2) Trials for which no individual participant data were available (information reported in published papers only) </h5> <p>Protocols were not available for any of the four trials, however a clinical summary report was provided for two trials from the sponsor (<a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>), and case report forms of data collected were provided for one trial by the sponsor (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>). All trials reported seizure and adverse event outcomes well, therefore we judged all five trials to be at low risk of selective reporting bias (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>). </p> </section> </section> <section id="CD001031-sec-0081"> <h4 class="title">Other potential sources of bias</h4> <p>We identified no other sources of bias for 13 of the 14 included trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). In one trial, it was unclear if all participants were receiving AED monotherapy treatment ('total number of AEDs' described in Table 1 of the publication), so we judged this trial to be at unclear risk of bias (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>). </p> </section> </section> <section id="CD001031-sec-0082"> <h3 class="title" id="CD001031-sec-0082">Effects of interventions</h3> <p>See: <a href="./full#CD001031-tbl-0001"><b>Summary of findings for the main comparison</b> Summary of findings: lamotrigine compared with carbamazepine for epilepsy (primary outcomes)</a>; <a href="./full#CD001031-tbl-0002"><b>Summary of findings 2</b> Summary of findings: lamotrigine compared with carbamazepine for epilepsy (secondary outcomes)</a> </p> <p>See <a href="#CD001031-tbl-0005">Table 3</a> for details regarding the number of individuals (with individual participant data (IPD)) contributing to each analysis, <a href="./full#CD001031-tbl-0001">summary of findings Table for the main comparison</a> for a summary of the results for the primary outcome 'time to treatment failure' (stratified by epilepsy type), and <a href="./full#CD001031-tbl-0002">summary of findings Table 2</a> for a summary of results for the secondary outcomes 'time to first seizure' and 'time to 12‐month remission'. </p> <div class="table" id="CD001031-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of participants included in analyses (trials providing individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to treatment failure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to 6‐</b> </p> <p><b>month remission<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to 12‐</b> </p> <p><b>month remission</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to 24‐</b> </p> <p><b>month remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>756</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>754</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1479</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1093</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2572</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1477</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1092</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2569</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1476</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1088</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2564</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1476</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1088</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2564</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>494</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>494</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>988</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>377</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>378</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>755</b> </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CBZ = carbamazepine; LTG = lamotrigine; NA: not applicable (trial duration not sufficient to measure the outcome). </p> <p>1. <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>, and <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, are of 24 weeks duration (approximately six months). The two trials are not included in the analyses of time to six‐month remission but are included in sensitivity analysis of seizure freedom at six months. </p> <p>2. Follow‐up data are missing for one participant in <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>. </p> <p>3. Treatment failure time missing for two participants and seizure data after follow‐up missing for one participant in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>. </p> <p>4. Seizure data after follow‐up missing for six participants in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>. </p> </div> </div> <p>For survival curve plots (cumulative incidence), see <a href="#CD001031-fig-0003">Figure 3</a>; <a href="#CD001031-fig-0004">Figure 4</a>; <a href="#CD001031-fig-0005">Figure 5</a>; <a href="#CD001031-fig-0006">Figure 6</a>; <a href="#CD001031-fig-0007">Figure 7</a>; <a href="#CD001031-fig-0008">Figure 8</a>; <a href="#CD001031-fig-0009">Figure 9</a>; <a href="#CD001031-fig-0010">Figure 10</a>; <a href="#CD001031-fig-0011">Figure 11</a>; <a href="#CD001031-fig-0012">Figure 12</a> and <a href="#CD001031-fig-0013">Figure 13</a>. We produced all cumulative incidence plots in Stata software version 14 (<a href="./references#CD001031-bbs2-0080" title="StataCorp . Stata Statistical Software: Release 14. CollegeStation, TX: StataCorp LP, 2015. ">Stata 2015</a>), using data from all trials providing IPD combined. We note that participants with event times of zero (i.e. those who withdrew from treatment or experienced seizure recurrence on the day of randomisation) are not included in the 'Numbers at risk' on the graphs and that data is not stratified by trial within these survival curve plots. All figures are intended to provide a visual representation of outcomes, extent of follow‐up and visual differences between seizure types. These graphs are not intended to show statistical significance and numerical values may vary compared to the text due to differences in methodology. </p> <div class="figure" id="CD001031-fig-0003"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 3</div> </div> <hr class="top"/><img alt="Time to treatment failure for any reason related to treatment (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG03.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure for any reason related to treatment (CBZ: Carbamazepine; LTG: Lamotrigine) </p> </div> </div> </div> <div class="figure" id="CD001031-fig-0004"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 4</div> </div> <hr class="top"/><img alt="Time to treatment failure due to adverse effects (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG04.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to adverse effects (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0005"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 5</div> </div> <hr class="top"/><img alt="Time to treatment failure due to lack of efficacy (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG05.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0006"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 6</div> </div> <hr class="top"/><img alt="Time to treatment failure for any reason related to treatment ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG06.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure for any reason related to treatment ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine) </p> </div> </div> </div> <div class="figure" id="CD001031-fig-0007"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 7</div> </div> <hr class="top"/><img alt="Time to treatment failure for due to adverse events ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG07.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to treatment failure for due to adverse events ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine) </p> </div> </div> </div> <div class="figure" id="CD001031-fig-0008"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 8</div> </div> <hr class="top"/><img alt="Time to first seizure (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG08.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to first seizure (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0009"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 9</div> </div> <hr class="top"/><img alt="Time to first seizure ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG09.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to first seizure ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0010"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 10</div> </div> <hr class="top"/><img alt="Time to six‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG10.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to six‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0011"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 11</div> </div> <hr class="top"/><img alt="Time to six‐month remission ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG11.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to six‐month remission ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0012"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 12</div> </div> <hr class="top"/><img alt="Time to 12‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG12.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 12‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <div class="figure" id="CD001031-fig-0013"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 13</div> </div> <hr class="top"/><img alt="Time to 24‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG13.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Time to 24‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> </div> <p>We calculated all hazard ratios (HRs) presented below by generic inverse variance fixed‐effect meta‐analysis unless otherwise stated. All analyses met the assumption of proportional hazards (addition of time‐varying covariate into the model non‐significant) unless stated below. </p> <section id="CD001031-sec-0083"> <h4 class="title">Primary outcome</h4> <section id="CD001031-sec-0084"> <h5 class="title">Time to treatment failure</h5> <p>For this outcome, a HR of less than 1 indicates a clinical advantage for lamotrigine.<br/> <br/> See <a href="#CD001031-tbl-0006">Table 4</a> for reasons for premature termination for 3768 participants in all 14 included trials (missing data for 19 participants from one trial (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>)), and how we classified these reasons in analysis of IPD. In one study, one participant randomised to lamotrigine had missing date and reason for treatment failure (<a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>), and in another study two participants had missing dates of treatment failure (one withdrew from lamotrigine due to remission of seizures and one withdrew from carbamazepine due to 'other' reasons not related to the allocated drug) (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). </p> <div class="table" id="CD001031-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Reason for early</b> </p> <p><b>termination<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Classification in time‐to‐event analyses: Event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Classification in time‐to‐event analyses: Censored</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> <p>response/seizure recurrence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both adverse events and inadequate response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol violation/non‐compliance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrew consent/participant choice<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> <p>(treatment‐related)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Illness or death (not treatment‐related)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission of seizures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> <p>(not treatment‐related)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed trial</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="14" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1447</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2144</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>905</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1624</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total (all)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3768</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>1. Primary reason for discontinuation specified ‐ participants may have withdrawn from allocated treatment for a combination of reasons. </p> <p>2. Reasons for treatment failure extracted from trial publications for <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>, <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>, and <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>. Individual participant data for reasons for treatment failure provided for other trials. </p> <p>3. Withdrawal of consent/participant choice classified as an event in this review but censored in included trial (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Sensitivity analysis classifying withdrawal of consent as a censored observation did not change the conclusions (results available on request). </p> <p>4. Other treatment‐related reasons: investigator choice (<a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), drug‐related death, pregnancy or perceived remission (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Specified only as 'other reason' for <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a> and <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>. </p> <p>5. Other reasons (not treatment‐related): epilepsy diagnosis changed (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Specified only as 'other reason' for <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, and for seven participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>. </p> <p>6. No information on whether participants withdrew from treatment or completed the study available for 19 participants </p> <p>7. One participant (randomised to LTG) with date and reason for treatment failure missing. </p> <p>8. Two participants with date of treatment failure missing so not included in analysis of time to treatment failure but with reasons for treatment failure provided (both censored: one withdrew from LTG due to remission of seizures, one withdrew from CBZ due to 'other' non‐treatment‐related reason). </p> </div> </div> <p>Times to treatment failure and reasons for treatment withdrawal or treatment failure were available for 2569 participants from the nine trials providing IPD (99.9% of 2572 participants with IPD available included in this analysis, see <a href="#CD001031-tbl-0005">Table 3</a>) (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). </p> <p>Out of 3768 participants for whom we had reasons for treatment failure or withdrawal, 1416 participants prematurely withdrew from treatment (38%): 697 out of 2144 (33%) participants randomised to lamotrigine and 719 out of 1624 (44%) participants randomised to carbamazepine. We deemed 1224 participants (86% of total treatment failures) to have withdrawn for reasons related to the allocated drug: 602 (86% of treatment failures) on lamotrigine and 622 (87% of treatment failures) on carbamazepine and we classified these reasons as 'events' in the analysis. The most common treatment‐related reason for treatment failure was adverse events: 624 withdrawals (44% of total treatment failures), 251 (36% of total treatment failures) on lamotrigine and 373 (52% of total treatment failures) on carbamazepine. </p> <p>We classed the other 192 reasons (95 on lamotrigine and 97 on carbamazepine) to be not related to the allocated drug and censored these participants in the analysis, in addition to the 2352 participants (1447 on lamotrigine and 905 on carbamazepine) who completed the trial without withdrawing or failing treatment. </p> <p>Considering time to treatment failure for any reason related to the treatment, the overall pooled HR (for 2569 participants providing IPD from nine trials) was 0.73 (95% confidence interval (CI) 0.64 to 0.82, P &lt; 0.00001, moderate‐quality evidence) indicating a statistically significant advantage with lamotrigine; in other words, treatment failure occurred significantly earlier on carbamazepine compared to lamotrigine in the nine included trials (<a href="./references#CD001031-fig-0014" title="">Analysis 1.1</a>). No important heterogeneity was present between trials (I<sup>2</sup>= 13%). </p> <p>Considering time to treatment failure due to adverse events (all other reasons for treatment failure or treatment withdrawal censored in analysis), the overall pooled HR (for 2569 participants providing IPD from nine trials) was 0.54 (95% CI 0.45 to 0.65, P &lt; 0.00001, moderate‐quality evidence) indicating a statistically significant advantage with lamotrigine; in other words, treatment failure due to adverse events occurred significantly earlier on carbamazepine compared to lamotrigine in the nine included trials (<a href="./references#CD001031-fig-0015" title="">Analysis 1.2</a>). No heterogeneity was present between trials (I<sup>2</sup>= 0%). </p> <p>Considering time to treatment failure due to lack of efficacy (all other reasons for treatment failure or treatment withdrawal censored in analysis), 1874 participants provided IPD from five trials;, no participants withdrew from one or both of the drugs due to lack of efficacy in four trials (<a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; see <a href="#CD001031-tbl-0006">Table 4</a>). The overall pooled HR was 1.03 (95% CI 0.75 to 1.41, P =0.86, moderate‐quality evidence) indicating no statistically significant difference between lamotrigine and carbamazepine (<a href="./references#CD001031-fig-0016" title="">Analysis 1.3</a>). No heterogeneity was present between trials (I<sup>2</sup>= 0%). </p> <section id="CD001031-sec-0085"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>Seizure type was missing for 85 participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, and nine participants were classified as having generalised onset seizures, even though the trial was designed to include only participants with focal onset seizures. Similarly, in <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, including participants with focal onset seizures, three participants were classified as having generalised onset seizures. The latter three participants were excluded from the subgroup analyses (all completed the trial). </p> <p>Considering time to treatment failure for any reason related to the treatment,for participants with generalised onset seizures (299 participants providing IPD from six trials), the pooled HR was 0.51 (95% CI 0.33 to 0.78, P = 0.002, I² = 18%, low‐quality evidence) and for participants with focal onset seizures (2182 participants providing IPD from nine trials) the pooled HR was 0.74 (95% CI 0.64 to 0.86, P = 0.0001, I² = 0%, moderate‐quality evidence) (<a href="./references#CD001031-fig-0017" title="">Analysis 1.4</a>), indicating a statistically significant advantage for lamotrigine over carbamazepine for both participants with focal onset and generalised onset seizures. Excluding the nine participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> with generalised onset seizures produced similar results and did not change the conclusions. </p> <p>The test for subgroup differences between focal and generalised onset seizures was not statistically significant (P = 0.10, I² = 63.4% for variability due to subgroup differences). </p> <p>The overall pooled HR (adjusted for epilepsy type for 2481 participants from nine trials) was HR 0.71 (95% CI 0.62 to 0.82, P &lt; 0.00001, moderate‐quality evidence). No important heterogeneity was present between trials overall (I<sup>2</sup> =3%). </p> <p>Considering time to treatment failure due to adverse events, for participants with generalised onset seizures (284 participants providing IPD from five trials), the pooled HR was 0.49 (95% CI 0.27 to 0.88, P = 0.002, I² = 52%, low‐quality evidence) and for participants with focal onset seizures (2182 participants providing IPD from nine trials) the pooled HR was 0.56 (95% CI 0.45 to 0.68, P&lt;0.00001, I² = 0%, moderate‐quality evidence) (<a href="./references#CD001031-fig-0018" title="">Analysis 1.5</a>), indicating a statistically significant advantage for lamotrigine over carbamazepine for both participants with focal onset and generalised onset seizures. Excluding the nine participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> with generalised onset seizures produced similar results and did not change the conclusions. </p> <p>The test for subgroup differences between focal and generalised onset seizures was not statistically significant (P = 0.70, I² =0% for variability due to subgroup differences). </p> <p>The overall pooled HR (adjusted for epilepsy type for 2466 participants from nine trials) was HR 0.55 (95% CI 0.45 to 0.66, P &lt; 0.00001, moderate‐quality evidence). No heterogeneity was present between trials overall (I² =0%). </p> <p>Due to small numbers of participants withdrawing from treatment due to lack of efficacy (see <a href="#CD001031-tbl-0006">Table 4</a>), and even smaller numbers within each seizure type subgroup, subgroup analysis by seizure type was not conducted for time to treatment failure due to lack of efficacy was not conducted. </p> </section> <section id="CD001031-sec-0086"> <h6 class="title">Sensitivity analyses</h6> <p>One study, <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, considered participants to have completed the trial and hence withdrew treatment if they experienced a seizure after week six. This does not correspond with the treatment failure definition recommended by the Commission on Antiepileptic Drugs of the International League Against Epilepsy (<a href="./references#CD001031-bbs2-0045" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>); therefore we performed sensitivity analysis excluding this trial from <a href="./references#CD001031-fig-0014" title="">Analysis 1.1</a> and <a href="./references#CD001031-fig-0017" title="">Analysis 1.4</a>. This sensitivity analysis produced similar results and did not change the conclusions. </p> <p>One included trial allocated participants to three treatment arms: 100 mg/day lamotrigine (LTG100), 200 mg/day lamotrigine (LTG 200) or 600 mg/day carbamazepine (CBZ) (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). See <a href="#CD001031-tbl-0007">Table 5</a> for a sensitivity analysis comparing the primary analysis (LTG arms pooled versus CBZ), LTG 100 with the other arms in the trial, LTG 200 with the other arms in the trial, LTG 200 versus CBZ and LTG 100 versus CBZ. When including these alternative estimates in meta‐analysis, the pooled result is numerically similar and the conclusions unchanged. </p> <div class="table" id="CD001031-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis ‐ Reunanen 1996</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time to treatment failure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time to 6‐month remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine (both arms)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.35 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.86 to 1.79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.36 to 1.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 200 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 100 mg + carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47 (0.25 to 0.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.67 to 1.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.24 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 100 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 200 mg + carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.63 to 1.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.29 (0.91 to 1.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (0.56 to 3.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 200 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.21 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (0.73 to 1.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.22 to 1.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 100 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.43 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.90 to 2.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.41 to 2.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>mg= milligrams per day; HR = hazard ratio; 95% CI = 95% confidence interval</p> </div> </div> <p>From four out of the five trials without IPD available, we indirectly estimated aggregate hazard ratios of time to treatment failure due to adverse events (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>), time to early termination (<a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>), and retention time (<a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>), and we extracted a published hazard ratio for time to all‐cause withdrawal (<a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). We were unable to estimate or extract an estimate from <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>. We note that these definitions do not directly correspond to our definition of treatment failure (i.e. all withdrawals and treatment failures are classed as events rather than only treatment‐related failures, see <a href="#CD001031-tbl-0006">Table 4</a>). Combining IPD and aggregate data, the pooled HR for 3391 participants from 13 included trials was 0.709 (95% CI 0.63 to 0.78, P &lt; 0.00001, I² = 27%) (<a href="./references#CD001031-fig-0019" title="">Analysis 1.6</a>). This indicates that the advantage to lamotrigine over carbamazepine remains and is robust to the inclusion of treatment failure data of variable definitions. </p> <p>Given the subjective nature of the outcome of time to treatment failure, an outcome which can be influenced by the participant and personnel, we conducted a further subgroup analysis separating the trials that were of a double‐blind design (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>, 1231 participants included in analyses) and those which were an open‐label design (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, 2160 participants included in analyses). Including treatment failure data from 13 trials (aggregate data from four trials), we found the following results. </p> <p> <ul id="CD001031-list-0017"> <li> <p>In the double‐blind trials, 242 out of 644 (38%) randomised participants withdrew from lamotrigine and 313 out of 587 (53%) withdrew from carbamazepine (in total 45% of participants withdrew from the randomised drug for any reason). </p> </li> <li> <p>In the open‐label trials, 368 out of 1248 (29%) randomised participants withdrew from lamotrigine and 369 out of 915 (40%) withdrew from carbamazepine (in total 34% of participants withdrew from the randomised drug for any reason). </p> </li> <li> <p>The advantage for lamotrigine over carbamazepine was slightly larger in the double‐blind trials (HR 0.65, 95% CI 0.56 to 0.75, P&lt;0.00001, I² = 24%) than in the open‐label trials (HR 0.76, 95% CI 0.65 to 0.90, P=0.001, I² = 21%) (<a href="./references#CD001031-fig-0020" title="">Analysis 1.7</a>). </p> </li> <li> <p>When including only the nine trials for which IPD were provided (double‐blind: <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>; open‐label: <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), the advantage for lamotrigine over carbamazepine was still slightly larger in the double‐blind trials (HR 0.68, 95% CI 0.57 to 0.81, P&lt;0.0001, I² = 36%) than the open‐label trials (HR 0.77, 95% CI 0.65 to 0.92, P=0.003, I² = 0%) </p> </li> </ul> </p> <p>These results suggest that the design of a trial (i.e. whether or not a participant and their clinician is aware of the treatment a participant is taking) may influence the withdrawal rates of the trial, with participants significantly more likely to withdraw from a double‐blind trial than an open‐label trial (45% versus 34%: risk ratio (RR) 1.32 (95% CI 1.22 to 1.44, P &lt; 0.00001)), and in turn this may influence the perceived effectiveness of the two drugs under comparison. </p> <p>Following reclassification of 152 individuals from seven trials with potentially misclassified generalised onset seizures (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), and 85 individuals with missing seizure type from one trial (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), the results of the two sensitivity analyses are shown in <a href="#CD001031-tbl-0008">Table 6</a>. In summary, the results overall by seizure type and for individuals with focal onset seizures are very similar. Also, following reclassification, the advantage for lamotrigine over carbamazepine in those with generalised onset seizures is reduced and the test of difference between subgroups is no longer significant. There is a statistically significant advantage for lamotrigine over carbamazepine in those with uncertain seizure type. </p> <div class="table" id="CD001031-tbl-0008"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ misclassification of seizure type</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to 6‐month remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Original analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.74, 95% CI (0.64 to 0.86)</p> <p>G: HR 0.51, 95% CI (0.33 to 0.78)</p> <p>O: HR 0.71, 95% CI (0.62 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 1.29, 95% CI (1.14 to 1.45)</p> <p>G: HR 0.98, 95% CI (0.65 to 1.48)</p> <p>O: HR 1.26, 95% CI (1.12 to 1.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.87, 95% CI (0.77 to 1.00)</p> <p>G: HR 0.78, 95% CI (0.55 to 1.11)</p> <p>O: HR 0.86, 95% CI (0.76 to 0.97)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of subgroup differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.73, df = 1 (P = 0.10), I² = 63.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.53, df = 1 (P = 0.22), I² = 34.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.37, df = 1 (P = 0.54), I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised onset and age at onset &gt; 30 reclassified<br/> as focal onset </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.72, 95% CI (0.62 to 0.83)</p> <p>G: HR 0.58, 95% CI (0.32 to 1.06)</p> <p>O: HR 0.71, 95% CI (0.62 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 1.25, 95% CI (1.11 to 1.41)</p> <p>G: HR 1.17, 95% CI (0.67 to 2.04)</p> <p>O: HR 1.25, 95% CI (1.11 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.85, 95% CI (0.75 to 0.97)</p> <p>G: HR 0.69, 95% CI (0.44 to 1.08)</p> <p>O: HR 0.84, 95% CI (0.74 to 0.95)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of subgroup differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.45, df = 1 (P = 0.50), I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.06, df = 1 (P = 0.81), I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.80, df = 1 (P = 0.37), I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised onset and age at onset &gt; 30 reclassified<br/> as uncertain seizure type </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.74, 95% CI (0.64 to 0.86)</p> <p>G: HR 0.58, 95% CI (0.32 to 1.06)</p> <p>U: HR 0.62, 95% CI (0.39 to 0.97)</p> <p>O: HR 0.72, 95% CI (0.63 to 0.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 1.29, 95% CI (1.14 to 1.45)</p> <p>G: HR 1.17, 95% CI (0.67 to 2.04)</p> <p>U: HR 0.88, 95% CI (0.58 to 1.33)</p> <p>O: HR 1.24, 95% CI (1.11 to 1.39)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.87, 95% CI (0.77 to 1.00)</p> <p>G: HR 0.69, 95% CI (0.44 to 1.08)</p> <p>U: HR 0.89, 95% CI (0.60 to 1.31)</p> <p>O: HR 0.86, 95% CI (0.76 to 0.97)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of subgroup differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.15, df = 2 (P = 0.56), I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 3.03, df = 2 (P = 0.22), I² = 33.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.02, df = 2 (P = 0.60), I² = 0%</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CI = confidence interval; F = focal onset seizures; G = generalised onset seizures; HR = hazard ratio; O = overall pooled result adjusted by seizure type; U = uncertain seizure type. </p> </div> </div> </section> </section> </section> <section id="CD001031-sec-0087"> <h4 class="title">Secondary outcomes</h4> <section id="CD001031-sec-0088"> <h5 class="title">Time to first seizure post randomisation</h5> <p>For this outcome, a HR of less than 1 indicates a clinical advantage for lamotrigine.</p> <p>Times to first seizure were available for 2564 participants from the nine trials providing IPD (99% of 2572 participants with IPD available included in this analysis, see <a href="#CD001031-tbl-0005">Table 3</a>) (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). </p> <p>Seizure recurrence was experienced by 1330 out of 2564 participants (52%), 805 out of 1476 (55%) on lamotrigine and 525 out of 1088 (48%) on carbamazepine. The overall pooled HR (for 2564 participants) was 1.22 (95% CI 1.09 to 1.37, P = 0.0004) indicating a statistically significant advantage to carbamazepine; in other words, participants experienced first seizure recurrence earlier on lamotrigine than carbamazepine in the nine included trials (<a href="./references#CD001031-fig-0021" title="">Analysis 1.8</a>). No heterogeneity was present between trials (I<sup>2</sup>= 0%). </p> <section id="CD001031-sec-0089"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>Seizure type was missing for 85 participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, and nine participants were classified as having generalised onset seizures, even though the trial was designed to include only participants with focal onset seizures. Similarly, in <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, including participants with focal onset seizures, three participants were classified as having generalised onset seizures. The latter three participants were excluded from the subgroup analyses (all completed the trial). </p> <p>For participants with generalised onset seizures (299 participants providing IPD from six trials), the pooled HR was 0.98 (95% CI 0.65 to 1.48, P = 0.94, moderate‐quality evidence), indicating no difference between the two drugs and for participants with focal onset seizures (2177 participants providing IPD from nine trials) the pooled HR was 1.29 (95% CI 1.14 to 1.45, P &lt; 0.0001, high‐quality evidence) (<a href="./references#CD001031-fig-0022" title="">Analysis 1.9</a>), indicating a statistically significant advantage for carbamazepine. There was no evidence of a difference between the subgroups (test for subgroup differences P = 0.22). Excluding the nine participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> with generalised onset seizures produced similar results and did not change the conclusions. </p> <p>The overall pooled HR (adjusted for epilepsy type for 2476 participants from nine trials) was 1.26 (95% CI 1.12 to 1.41, P &lt; 0.0001, high‐quality evidence). No heterogeneity was present between trials overall or by subgroups (I<sup>2</sup> =0%). </p> </section> <section id="CD001031-sec-0090"> <h6 class="title">Sensitivity analyses</h6> <p>Data from one trial could not be included for this outcome as the dates of seizures that occurred during the first four weeks of the trial were not supplied (<a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>). A total of 216 participants (lamotrigine: 160, carbamazepine: 56) (35% of the number in the trial) experienced at least one seizure during the first four weeks, however dates of these seizures were not supplied. Therefore, for <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, this outcome is calculated as 'time to first seizure after four weeks of treatment' rather than 'time to first seizure after randomisation'. Excluding this trial in sensitivity analysis produces very similar numerical results and the conclusions are unchanged. </p> <p>One included trial allocated participants to three treatment arms: 100 mg/day lamotrigine (LTG100), 200 mg/day lamotrigine (LTG 200) or 600 mg/day carbamazepine (CBZ) (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). See <a href="#CD001031-tbl-0007">Table 5</a> for sensitivity analysis comparing the primary analysis (LTG arms pooled versus CBZ), LTG 100 with the other arms in the trial, LTG 200 with the other arms in the trial, LTG 200 versus CBZ and LTG 100 versus CBZ. When including these alternative estimates in meta‐analysis, the pooled result is numerically similar and the conclusions unchanged. </p> <p>From three out of the five trials without IPD available, we indirectly estimated aggregate hazard ratios of time to first seizure from published graphs in two trials (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>), and extracted a published hazard ratio of time to first seizure (<a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). We were unable to estimate or extract an estimate from <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a> or <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>. Combining IPD and aggregate data, the pooled HR for 3216 participants from the 12 included trials was 1.24 (95% CI 1.12 to 1.37, P &lt; 0.00001, I<sup>2</sup>=15%) (<a href="./references#CD001031-fig-0023" title="">Analysis 1.10</a>). This again shows an advantage to carbamazepine over lamotrigine. </p> <p>We were able to calculate or extract seizure freedom throughout the whole trial for all trials included in this review (in <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, it was not stated whether any participants who withdrew experienced seizure recurrence, therefore we have conducted an intention‐to‐treat analysis of seizure freedom rather than seizure recurrence). For consistency with the primary analysis of the outcome, in <a href="./references#CD001031-fig-0024" title="">Analysis 1.11</a> we have swapped event and non‐event so that a RR less than 1 indicates a clinical advantage for lamotrigine. </p> <p>The pooled RR of seizure freedom (for 3760 participants from 14 trials) is 1.11 (95% CI 1.04 to 1.18, P = 0.0006, I<sup>2</sup>=53%), indicating a statistically significant advantage to carbamazepine. Therefore, following the inclusion of seizure freedom/recurrence data from all included trials, the advantage to carbamazepine remains. There is now a large amount of heterogeneity present between the trials, which was not present in the IPD meta‐analysis (I<sup>2</sup> =53%, <a href="./references#CD001031-fig-0024" title="">Analysis 1.11</a>). This may reflect the variable follow‐up lengths of the trials (from 24 weeks to over six years), or may reflect the way the aggregate data are presented in some of the trials; for example in <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, seizure freedom rates are presented only for those who have completed the trial. </p> <p>Following reclassification of 152 individuals from seven trials with potentially misclassified generalised onset seizures (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), and 85 individuals with missing seizure type from one trial (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), the results of the two sensitivity analyses are shown in <a href="#CD001031-tbl-0008">Table 6</a>. In summary, the results overall by seizure type and for individuals with focal onset seizures are very similar. Following reclassification, there is a slight advantage to carbamazepine, which is not statistically significant, for those with generalised onset seizures. For those with uncertain seizure type, there is a slight advantage to lamotrigine that is not statistically significant. </p> </section> </section> <section id="CD001031-sec-0091"> <h5 class="title">Time to achieve six‐month remission</h5> <p>For this outcome, a HR of less than 1 indicates a clinical advantage for carbamazepine.</p> <p>Times to six‐month remission were available for 1793 participants from the seven trials providing IPD (70% of 2572 participants with IPD available included in this analysis, see <a href="#CD001031-tbl-0005">Table 3</a>) (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). The remaining two trials were of 24 weeks duration so were not included in the analysis of time to six‐month remission but are included in the sensitivity analysis of seizure freedom (<a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>). </p> <p>Six‐month remission was achieved by 1113 out of 1793 participants (62%), 572 out of 955 (60%) on lamotrigine and 541 out of 838 (65%) on carbamazepine. The overall pooled HR (for 1793 participants) was 0.84 (95% CI 0.74 to 0.94, P = 0.003) indicating a statistically significant advantage to carbamazepine; in other words, participants experienced six‐month remission earlier on lamotrigine than carbamazepine in the seven included trials (<a href="./references#CD001031-fig-0025" title="">Analysis 1.12</a>). No heterogeneity was present between trials (I<sup>2</sup>= 0%). </p> <section id="CD001031-sec-0092"> <h6 class="title">Subgroup analyses: seizure type (focal versus generalised onset)</h6> <p>Seizure type was missing for 85 participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, and nine participants were classified as having generalised onset seizures, even though the trial was designed to include only participants with focal onset seizures. </p> <p>For participants with generalised onset seizures (254 participants providing IPD from five trials), the pooled HR was 0.78 (95% CI 0.55 to 1.11, P = 0.16, I<sup>2</sup> =0%), indicating an advantage to carbamazepine that is not statistically significant, and for participants with focal onset seizures (1454 participants providing IPD from seven trials) the pooled HR was 0.87 (95% CI 0.77 to 1.00, P = 0.04, I<sup>2</sup> =25%) (<a href="./references#CD001031-fig-0026" title="">Analysis 1.13</a>), indicating a statistically significant advantage for carbamazepine. There was no evidence of a difference between the subgroups (test for subgroup differences P = 0.54). Excluding the nine participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> with generalised onset seizures produced similar results and did not change the conclusions. </p> <p>The overall pooled HR (adjusted for epilepsy type for 1708 participants from seven trials) was 0.86 (95% CI 0.76 to 0.97, P = 0.02) (<a href="./references#CD001031-fig-0026" title="">Analysis 1.13</a>) . No heterogeneity was present between trials overall (I<sup>2</sup>= 0%). </p> </section> <section id="CD001031-sec-0093"> <h6 class="title">Sensitivity analyses</h6> <p>One included trial allocated participants to three treatment arms, 100 mg/day lamotrigine (LTG 100), 200 mg/day lamotrigine (LTG 200) or 600 mg/day carbamazepine (CBZ) (<a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>). See <a href="#CD001031-tbl-0007">Table 5</a> for a sensitivity analysis comparing the primary analysis (LTG arms pooled versus CBZ), LTG 100 with the other arms in the trial, LTG 200 with the other arms in the trial, LTG 200 versus CBZ and LTG 100 versus CBZ. When including these alternative estimates in meta‐analysis, the pooled result is numerically similar and the conclusions unchanged. </p> <p>We were able to calculate or extract seizure freedom at six months for all trials included in this review (estimated from the graph published in <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>). A RR less than 1 indicates a clinical advantage for carbamazepine. </p> <p>The pooled RR of seizure freedom at six months (for 3760 participants from 14 trials) is RR 0.96 (95% CI 0.89 to 1.03, P = 0.25, I<sup>2</sup> =21%) (<a href="./references#CD001031-fig-0027" title="">Analysis 1.14</a>), indicating no statistically significant advantage to either drug. As above, we note that the way the aggregate data are presented in some trials may influence the results; for example in <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, seizure freedom rates are presented only for those who have completed the trial. </p> <p>Following reclassification of 152 individuals from seven trials with potentially misclassified generalised onset seizures (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), and 85 individuals with missing seizure type from one trial (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), the results of the two sensitivity analyses are shown in <a href="#CD001031-tbl-0008">Table 6</a>. In summary, the results overall by seizure type are very similar to the subgroup analysis described above and the conclusions are unchanged. For those with uncertain seizure type, there is a slight advantage to carbamazepine that is not statistically significant. </p> <p>In <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>, analysis adjusted for epilepsy type, there was some evidence that the proportional hazards assumption of the Cox model may have been violated; the P value of the time‐varying covariate was 0.051. However, the time varying covariate is not significant in the analysis without adjustment for seizure type (P = 0.146). </p> <p>Following visual inspection of a cumulative incidence plot (not shown but available from the authors), the curves appear to cross around 200 days, when less than 20% of randomised participants remain at risk in the trial. Therefore, we conclude that the crossing of the curves is likely to be due to small numbers of participants with generalised seizure types and small numbers remaining in the trial leading to changes and events being magnified at this time. The proportional hazards assumption of the Cox model was satisfied for all other trials included in analysis. </p> </section> </section> <section id="CD001031-sec-0094"> <h5 class="title">Time to achieve 12‐month (one‐year) remission</h5> <p>For this outcome, a HR of less than 1 indicates a clinical advantage for carbamazepine.</p> <p>Times to 12‐month remission were available for 988 participants from the two trials providing IPD of sufficient duration (70% of 2572 participants with IPD available included in this analysis, see <a href="#CD001031-tbl-0005">Table 3</a>) (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). </p> <p>Twelve‐month remission was achieved by 564 out of 998 participants (57%), 276 out of 474 (58%) on lamotrigine and 288 out of 474 (61%) on carbamazepine. The overall pooled HR (for 998 participants) was HR 0.91 (95% CI 0.77 to 1.07, P = 0.26, high‐quality evidence), indicating an advantage to carbamazepine that was not statistically significant (<a href="./references#CD001031-fig-0028" title="">Analysis 1.15</a>). No heterogeneity was present between trials (I<sup>2</sup>= 0%). </p> <section id="CD001031-sec-0095"> <h6 class="title">Subgroup analysis and sensitivity analysis</h6> <p>All participants had focal onset seizures in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>; and in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, the design was to include only those with focal onset seizures. However, seizure type was missing for 85 participants, and nine participants were classified as having generalised onset seizures. Given the small numbers in the generalised onset group (which are likely to have been misclassified), we did not perform a sensitivity analysis by seizure type. </p> <p>Instead we performed a subgroup analysis of those with focal seizures specified at baseline (all participants in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>, and 661 participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>) and those with uncertain seizure type (85 with missing seizure type and nine with generalised onset seizures in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). </p> <p>For those with uncertain seizure type (94 participants providing IPD from one trial), the HR was 0.81 (95% CI 0.47 to 1.37, P = 0.43) (<a href="./references#CD001031-fig-0029" title="">Analysis 1.16</a>), indicating an advantage to carbamazepine that is not statistically significant. For those with focal onset seizures (894 participants providing IPD from two trials), the pooled HR was 0.91 (95% CI 0.77 to 1.09, P = 0.31, I<sup>2</sup>= 0%), also indicating an advantage to carbamazepine that is not statistically significant (<a href="./references#CD001031-fig-0029" title="">Analysis 1.16</a>). There was no evidence of a difference between the subgroups (test for subgroup differences P = 0.66). </p> </section> </section> <section id="CD001031-sec-0096"> <h5 class="title">Time to achieve 24‐month (two‐year) remission</h5> <p>For this outcome, a HR of less than 1 indicates a clinical advantage for carbamazepine.</p> <p>Times to 24‐month remission were available for 755 participants from one trial providing IPD of sufficient duration (29% of 2572 participants with IPD available included in this analysis, see <a href="#CD001031-tbl-0005">Table 3</a>) (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). </p> <p>Twenty‐four month remission was achieved by 296 out of 755 participants (39%), 149 out of 377 (40%) on lamotrigine and 147 out of 378 (39%) on carbamazepine. The overall HR (for 755 participants from one trial) was 1.00 (95% CI 0.80 to 1.25, P = 0.99), indicating no statistically significant difference between the drugs (<a href="./references#CD001031-fig-0030" title="">Analysis 1.17</a>). </p> <section id="CD001031-sec-0097"> <h6 class="title">Subgroup analysis and sensitivity analysis</h6> <p>Seizure type was missing for 85 participants from <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, and nine participants were classified as having generalised onset seizures, even though the trial was designed to include only participants with focal onset seizures. </p> <p>Given the small numbers in the generalised onset group (which are likely to have been misclassified), we did not perform a sensitivity analysis by seizure type. </p> <p>Instead we performed a subgroup analysis of those with focal seizures specified at baseline (661 participants) and those with uncertain seizure type (85 with missing seizure type and nine with generalised onset seizures). For those with uncertain seizure type (94 participants providing IPD from one trial), the HR was 0.86 (95% CI 0.44 to 1.67, P = 0.65) (<a href="./references#CD001031-fig-0031" title="">Analysis 1.18</a>), indicating an advantage to carbamazepine that is not statistically significant. For those with focal onset seizures (661 participants providing IPD from two trials), the pooled HR was 1.06 (95% CI 0.83 to 1.35, P = 0.66), indicating an slight advantage to lamotrigine that is not statistically significant (<a href="./references#CD001031-fig-0031" title="">Analysis 1.18</a>). There was no evidence of a difference between the subgroups (test for subgroup differences P = 0.57). </p> <p>In <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> (analyses with and without adjustment for epilepsy type), there was evidence that the proportional hazards assumption of the Cox model may have been violated; the P value of the time‐varying covariate was 0.025. </p> <p>Following visual inspection of a cumulative incidence plot (<a href="#CD001031-fig-0013">Figure 13</a>), the curves appear to cross around 1200 days. Considering the distribution of events, all 24‐month remission events occurred before 1200 days; none of the 164 participants (82 in each treatment group) experienced remission after 1200 days. This observation would explain the apparent change in treatment effect over time (i.e. a difference in censoring times). The proportional hazards assumption of the Cox model was satisfied for all other trials included in analysis. </p> </section> </section> <section id="CD001031-sec-0098"> <h5 class="title">Incidence of adverse events</h5> <p>We were provided with individual participant data for adverse events experienced during the trial for nine trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), and we extracted information relating to adverse events from the remaining five publications (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>). Due to the wide range of events reported in the trials and the different methods of recording adverse events, we have not analysed adverse event data in meta‐analysis and provide a narrative report. </p> <p>Seven trials provided very detailed information regarding all adverse events experienced by all participants during the trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). This information is summarised in <a href="#CD001031-tbl-0009">Table 7</a>, <a href="#CD001031-tbl-0010">Table 8</a> and <a href="#CD001031-tbl-0011">Table 9</a>. </p> <div class="table" id="CD001031-tbl-0009"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of adverse events experienced (seven trials providing detailed individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number experiencing</b> </p> <p><b>adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of</b> </p> <p><b>adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of adverse events</b> </p> <p><b>per person (range)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of drug‐related</b> </p> <p><b>adverse events<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of adverse</b> </p> <p><b>events requiring action/</b> </p> <p><b>treatment change</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of patients</b> </p> <p><b>needing a treatment</b> </p> <p><b>change/dose change</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>388</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>710</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>694</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1038</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1339</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>665</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>779</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>770</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>673</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>CBZ = carbamazepine; LTG = lamotrigine; NA = information not available.</p> <p>1. In <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>, <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> and <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> adverse events that are "definitely related", in <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> and <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> "a reasonable possibility" that adverse events are treatment‐related and in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> adverse events are "related, probably related or possibility related". </p> </div> </div> <div class="table" id="CD001031-tbl-0010"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Most commonly occurring adverse events (trials providing detailed individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Most commonly occurring adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. "><b>Brodie 1995 A</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. "><b>Brodie 1995 B</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. "><b>Brodie 1999</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. "><b>Nieto‐Barrera 2001</b> </a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Accidental injury/fracture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aggression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia/weight loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety/depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aphasia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ataxia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest infection/bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cold/influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concentration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough/wheeze</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizzy/faint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsy/fatigued</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal disturbances</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hair loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache/migraine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impotence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased/worsened seizures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney/urinary problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood/behavioural change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pins and needles/tingling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash/skin problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep problems/dreams</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Throat/tonsil infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor/twitch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual disturbance/nystagmus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Table of most commonly occurring adverse events split into two for formatting reasons.</p> <p>Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the same type of adverse event multiple times). </p> <p>LTG = lamotrigine; CBZ = carbamazepine</p> <p>Most common adverse events are defined as events reported 10 or more times in at least one of the seven trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Less commonly reported adverse events are not summarised in this table but details are available on request from the review authors. General terminology for the type of adverse events was defined by the review authors based on the individual participant data provided. </p> </div> </div> <div class="table" id="CD001031-tbl-0011"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Most commonly occurring adverse events continued (trials providing detailed individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Most commonly occurring adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. "><b>Reunanen 1996</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. "><b>SANAD A 2007</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] "><b>Werhahn 2015</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Total (across seven studies)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Accidental injury/fracture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aggression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia/weight loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety/depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aphasia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ataxia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest infection/bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cold/influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concentration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough/wheeze</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizzy/faint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsy/fatigued</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>562</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal disturbances</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hair loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache/migraine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impotence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased/worsened seizures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney/urinary problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood/behavioural change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pins and needles/tingling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash/skin problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep problems/dreams</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Throat/tonsil infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor/twitch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual disturbance/nystagmus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>Table of most commonly occurring adverse events split into two for formatting reasons.</p> <p>Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the same type of adverse event multiple times). </p> <p>LTG = lamotrigine; CBZ = carbamazepine</p> <p>Most common adverse events are defined as events reported 10 or more times in at least one of the seven trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Less commonly reported adverse events are not summarised in this table but details are available on request from the review authors. General terminology for the type of adverse events was defined by the review authors based on the individual participant data provided. </p> </div> </div> <p>The most common adverse events, reported 10 or more times in at least one of the seven trials are: accidental injury/fracture, aggression, anorexia/weight loss, anxiety/depression, aphasia, ataxia, chest infection/bronchitis, cold/influenza, concentration, confusion, cough/wheeze, dental, dizzy/faint, drowsy/fatigued, gastrointestinal disturbances, hair loss, headache/migraine, impotence, increased/worsened seizures, kidney/urinary problems, memory problems, menstrual problems, mood/behavioural change, nausea/vomiting, pain, pins and needles/tingling, rash/skin problems, sleep problems/dreams, throat/tonsil infection, tremor/twitch, visual disturbance/nystagmus, weight gain. </p> <p>The five most commonly reported adverse events on both drugs were: dizzy/faint, drowsy/fatigued, gastrointestinal disturbances, headache/migraine, and rash/skin problems. Across all the trials, the rates of these common adverse events were similar for the two drugs. We did not statistically analyse adverse event data. </p> <p>A summary for the other seven trials is as follows.</p> <p>In <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>, five events related to treatment were reported in three participants taking lamotrigine (all skin rashes). Eight events related to treatment were reported in six participants taking carbamazepine (six with tiredness/lethargy, two with skin rashes). All adverse events were described as non‐serious. </p> <p>In <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>, two participants taking lamotrigine had adverse events: somnolence and dizziness, respectively. Twelve participants in the carbamazepine group had adverse events: three with nausea and vomiting, three with skin eruptions, two with confusion and one with overdose symptoms who was hospitalised </p> <p>In <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>, adverse events reported were rash (12.8% of participants on lamotrigine and 8.6% of participants on carbamazepine), dizziness (6.8% of participants on lamotrigine and 10.1% of participants on carbamazepine), dyspnoea (0.4% of participants on lamotrigine and 7.0% of participants on carbamazepine), somnolence (0 of participants on lamotrigine and 4.7% of participants on carbamazepine), headache (5.3% of participants on lamotrigine and 0% of participants on carbamazepine), acne (1.1% of participants on lamotrigine and 0% of participants on carbamazepine), asthenia (0.8% of participants on lamotrigine and 1.6% of participants on carbamazepine), oesophageal ulceration (0.4% of participants on lamotrigine and 1.6% of participants on carbamazepine), abnormal liver function (0% of participants on lamotrigine and 1.6% of participants on carbamazepine). Non‐fatal serious adverse events were reported in 4 participants on lamotrigine; three with rash and one with post‐ictal psychosis. All serious adverse events were deemed to be related to treatment. </p> <p>In <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>, four participants taking lamotrigine reported skin rash (related to treatment), five participants taking carbamazepine reported skin rash (related to treatment) and one participant on carbamazepine reported mitral stenosis (unrelated to treatment). </p> <p>In <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, systemic and neurologic toxicities experienced were weight gain or weight loss (87.4% of participants on lamotrigine and 80.1% of carbamazepine), gastrointestinal problems (33.9% on lamotrigine and 32.2% on carbamazepine), hypersensitivity/severe hypersensitivity (3.3% on lamotrigine and 13.4% on carbamazepine), water retention (10.4% on lamotrigine and 8.8% on carbamazepine), hyponatraemia (6.6% on lamotrigine and 11.1% on carbamazepine), impotence (4.4% on lamotrigine and 7.6% on carbamazepine), and renal or liver disease (1.6% on lamotrigine and 4.1% on carbamazepine). </p> <p>In <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>, for lamotrigine, 82 participants reported 378 events: 36 participants reported 53 gastrointestinal events, 20 participants reported 26 infections, 19 participants reported 36 musculoskeletal events, 44 participants reported 111 events of the nervous system, 13 participants reported 23 psychiatric events, 12 participants reported 20 skin problems, 11 participants reported 11 vascular disorders and two participants reported two events of the immune system and 24 participants reported 37 other events. For carbamazepine, 79 participants reported 310 events: 29 participants reported 46 gastrointestinal events, 13 participants reported 23 infections, 18 participants reported 29 musculoskeletal events, 45 participants reported 76 events of the nervous system, 12 participants reported 16 psychiatric events, 21 participants reported 25 skin problems, five participants reported six vascular disorders and 11 participants reported 14 events of the immune system and 27 participants reported 41 other events. For both treatments around half of the events were thought to be related to treatment, particularly dizziness, rash, headache, somnolence and gastrointestinal symptoms. </p> <p>In <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>, the most frequent adverse events for lamotrigine were fatigue (14.8% of participants), rash, headache and nausea (5.7%), nervousness, sleep disorders, pruritus, alopecia and dizziness (4.5%). Three severe adverse events were reported, all possibly related to treatment (nausea and diarrhoea, leucopenia and fatigue). Most frequent adverse events for carbamazepine were fatigue (43.2%), amnesia and pruritus (10.2%), rash (9.1%), abnormal thoughts and abnormal gait (8%). Seven severe adverse events were reported – four were almost certainly related to treatment (rash, dermatitis, abnormal gait and fatigue), two were probably related to treatment (rash and hyponatraemia) and one was unrelated (astrocytoma). </p> <p>Serious adverse events or adverse events requiring hospitalisation were reported in the seven trials providing detailed IPD (we note that some events were reported multiple times by participants), as follows. </p> <p>In <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>, 16 serious adverse events were reported in seven participants. On lamotrigine, there were 13 events in five participants: suicidal ideation (unknown if related to treatment), knee arthroscopy (not related to treatment), recurrent seizures (related to treatment), aggression (unknown if related to treatment) and headache, diplopia, vertigo, photophobia and vomiting (in a single participant, all related to treatment) and on carbamazepine there were three events in two participants (meningioma not related to treatment and pain possibly related to treatment). </p> <p>In <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>, seven serious adverse events were reported in six participants. On lamotrigine, there were five events in four participants: haematemesis and stomach ulcer (both related to treatment), appendicitis and tumour in two participants (none related to treatment). On carbamazepine, there were, two events in two participants: meningioma and tumour (neither related to treatment). </p> <p>In <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>, 69 serious adverse events were reported in 36 participants. On lamotrigine, there were 36 events in 21 participants: six events in four participants were thought to be related to treatment (sickness, abdominal pain and vomiting in one participant, fracture, seizure recurrence and paranoia) and 30 events in 17 participants were not thought to be related to treatment (asthma, stroke in four participants, glaucoma and vomiting in one participant, urinary retention in one participant, chest infection and vomiting blood in one participant, fracture in two participants, seizure recurrence, vomiting, myalgia and chest pain in one participant, bronchospasm, atrial fibrillation and cardiac failure in one participant, tachycardia in one participant, myocardial infarction and pancreatitis in one participant). On carbamazepine, there were 33 events in 15 participants: eight events in four participants were thought to be related to treatment (rashes in three participants and diarrhoea and vomiting in one participant) and 25 events in 11 participants were not thought to be related to treatment (cerebrovascular accident and upper respiratory tract infection in two participants, leg cramps, myocardial infarction and collapse in one participant, stroke and bronchopneumonia in one participant, dizziness and syncope in one participant, high temperature, chest infection and vomiting in one participant, hyperglycaemic coma, pneumonia and septicaemia in one participant, angina and atrial fibrillation in one participant, falls and vagueness in one participant, ventricular failure and intestinal obstruction in one participant, and seizure recurrence in two participants). </p> <p>In <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, 40 serious adverse events were reported in 32 participants. On lamotrigine, there were 27 events in 23 participants: six events in five participants were thought to be related to treatment (rash, raised intracranial pressure, increased seizures, allergic reaction and vertigo) and 23 events in 18 participants were not thought to be related to treatment (change in seizure type, gastric infection, two participants with back pain, broken clavicle, febrile convulsions, tonic‐clonic seizures and related injury, intracranial bleeding, haematoma, low pressure of shunt system, complex seizure, traffic accident, pneumonia, gingivostomatitis, fractured elbow, infection, two sudden deaths and cerebral tumour). On carbamazepine, there were 13 events in nine participants: five events in three participants were thought to be related to treatment (diarrhoea and difficulty walking, allergic reaction and atrial fibrillation and hydrothorax) and eight events in six participants were not thought to be related to treatment (tumour, pneumonia, infection, febrile convulsions, embolisation, hepatitis B and cardiac arrest). </p> <p>In <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>, 12 serious adverse events were reported in seven participants (none related to treatment). On lamotrigine, there were 10 events in five participants: haematemesis and cerebral infarct, uterine bleeding and hysterectomy, cerebral and retinal emboli, pain and postoperative infection, and stroke. Three life‐threatening events were reported in three participants on lamotrigine (none related to treatment): carbon monoxide poisoning (fatal), myocardial infarction (fatal) and brain tumour. On carbamazepine, there were two events in two participants: pulmonary oedema and angioma. </p> <p>In <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, 177 events resulting in hospitalisation were reported for 99 participants (it is not stated if the events were related to treatment). On lamotrigine, there were 86 events in 53 participants: worsening of seizures in 13 participants, seizure‐related injury in seven participants, cardiovascular events in five participants, stomach ulcer in two participants, infection in two participants, attempted suicide in one participant, rectal bleeding in one participant, pneumonia in one participant; swollen ear in one participant, enlarged prostate in one participant, bowel infection in one participant, malignancy in one participant, legionnaires disease in one participant, haemorrhage in one participant, stroke in one participant, meningioma in one participant, vomiting in one participant, hepatitis in one participant, constipation in one participant, allergic rash in one participant, aneurysm in one participant, vertigo in one participant, carcinoma in one participant, occipital arteriovenous malformations in one participant, Bell's palsy in one participant, allergic rash in one participant, lymphadenopathy in one participant, fractured clavicle in one participant, childbirth in one participant, miscarriage in one participant and toxicity in one participant. On carbamazepine, there were 91 events in 46 participants: worsening of seizures in 12 participants, cardiovascular events in five participants, attempted suicide in three participants, seizure‐related injury in three participants, allergic rash in two participants, antiphospholipid syndrome in one participant, arthritis in one participant, stomach cancer in one participant, urinary tract infection in one participant, disorientation in one participant, psychotic illness in one participant, exacerbation of chronic obstructive pulmonary disease in one participant, hysterectomy in one participant, torsion of testis in one participant, myringotomy in one participant, infection in one participant, worsening of seizures and visual disturbance in one participant, constipation in one participant, low serum in one participant, breast cancer in one participant, abdominal pain in one participant, ataxia in one participant, child birth in one participant, pneumonia in two participant and headache in one participant. </p> <p>In <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>, 120 serious adverse events were reported in 70 participants. On lamotrigine, there were 58 events in 34 participants: two events in two participants were thought to be related or possibly related to treatment (psychiatric disorder and hallucination) and 56 events in 33 participants were not thought to be related to treatment (worsening seizures in eight participants, gastroenteritis in one participant, transient ischaemic attack in two participants, myocardial infarction in two participants, alcohol poisoning in one participant, prostatic hyperplasia in one participant, sudden hearing loss in one participant, sudden death in one participant, cerebral infarction in one participant, astrocytoma in one participant, brain neoplasm in one participant, radius fracture in one participant, bursitis in one participant, head injury in one participant, osteoarthritis in one participant, pneumonia in one participant, urinary tract infection in one participant, herpes in one participant, angina in one participant, asthma in one participant, memory impairment in one participant, intestinal obstruction in one participant, vertebral fracture in one participant, suicidal ideation in one participant, meningioma in one participant and hernia in one participant). On carbamazepine, there were 62 events in 36 participants: four events in three participants were thought to be related to treatment (hepatic enzyme increased, liver disorder and allergic rash), 13 events in four participants were thought to be probably related to treatment (diarrhoea in one participant, headache and hyponatraemia in one participant, dizziness and nausea in two participants), eight events in five were thought to be possibly related to treatment (purpura in one participant, gastroenteritis in two participants, confusion in one participant, lupus erythematosus in one participant), and 28 events in 25 participants were not thought to be related to treatment (worsening seizures in six participants, pneumonia in two participants, sleep apnoea in one participant, cholecystitis in one participant, abdominal pain and nausea in one participant, pain in one participant, spine fusion surgery in one participant, acute coronary syndrome in one participant, gastrointestinal haemorrhage in one participant, death in one participant, hypertension in one participant, device occlusion in one participant, carcinoma in one participant, intestinal obstruction in one participant, melanoma in one participant, dementia in one participant, infectious peritonitis in one participant, pulmonary embolism in one participant, renal cancer in one participant and constipation in one participant). </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD001031-sec-0099" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD001031-sec-0099"></div> <section id="CD001031-sec-0100"> <h3 class="title" id="CD001031-sec-0100">Summary of main results</h3> <p>The results of this review provide statistically significant, but moderate‐ to low‐quality evidence of an advantage for lamotrigine over carbamazepine for our primary global effectiveness outcome, time to treatment failure. Considering time to treatment failure for any reason related to treatment, for 2569 participants providing individual participant data (IPD) from nine trials, the pooled hazard ratio (HR) was 0.73 (95% confidence interval (CI) 0.64 to 0.82, P &lt; 0.00001, moderate‐quality evidence). This advantage was also present in the 2182 participants with focal onset seizures (pooled HR 0.74, 95% CI 0.64 to 0.86, P = 0.0001, moderate‐quality evidence) and the 299 participants with generalised onset seizures (pooled HR 0.51, 95% CI 0.33 to 0.78, P = 0.002, low‐quality evidence) from the nine trials providing IPD. </p> <p>The advantage also remained when incorporating aggregate data from four trials for which IPD were not available, allowing for alternative definitions of treatment failure from the definition used in this review (<a href="./references#CD001031-bbs2-0045" title="ILAE Commission on Antiepileptic Drugs. Considerations on designing clinical trials to evaluate the place of new antiepileptic drugs in the treatment of newly diagnosed and chronic patients with epilepsy. Epilepsia1998;39(7):799‐803. ">ILAE 1998</a>), and allowing for blinded trial design. </p> <p>There was also an advantage for lamotrigine over carbamazepine when considering time to treatment failure due to adverse events in all 2569 participants (pooled HR 0.54 (95% CI 0.45 to 0.65, P &lt; 0.00001, moderate‐quality evidence)), the 2182 participants with focal onset seizures (pooled HR 0.56 (95% CI 0.45 to 0.68, P&lt;0.00001, moderate‐quality evidence) and the 299 participants with generalised onset seizures (pooled HR 0.49 (95% CI 0.27 to 0.88, P = 0.002, low‐quality evidence) but no difference between lamotrigine and carbamazepine when considering time to treatment failure due to lack of efficacy in 1874 participants in five trials where at least one participant on each treatment failed treatment due to lack of efficacy (pooled HR 1.03 (95% CI 0.75 to 1.41, P =0.86), moderate‐quality evidence). </p> <p>The results of this review provide statistically significant and high‐quality evidence of an advantage for carbamazepine over lamotrigine for our secondary efficacy outcomes, time to first seizure (pooled HR for 2564 participants: 1.22, 95% CI 1.09 to 1.37, P = 0.0004, high‐quality evidence) and time to six‐month remission (pooled HR for 1793 participants: 0.84, 95% CI 0.74 to 0.94, P = 0.003, high‐quality evidence). As above, this advantage was present in the subgroup of participants with focal onset seizures (high‐quality evidence), but in the smaller subgroup of participants with generalised onset seizures we found no significant difference between the drugs (moderate‐quality evidence). </p> <p>We found no statistically significant difference between the drugs for the longer‐term outcomes of time to 12‐month remission and time to 24‐month remission (high‐quality evidence); however fewer data were available for inclusion in analyses at these time points due to the short duration of most included trials. </p> <p>The most commonly reported adverse events for both of the drugs across all of the included trials were dizziness, fatigue, gastrointestinal disturbances, headache and skin problems. The rate of adverse events and serious adverse events was similar across the two drugs. </p> </section> <section id="CD001031-sec-0101"> <h3 class="title" id="CD001031-sec-0101">Overall completeness and applicability of evidence</h3> <p>We have gratefully received individual participant data (IPD) for 2572 individuals (68% of 3787 individuals from all eligible trials) from the authors or sponsors of nine trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), which included a comparison of lamotrigine with carbamazepine for the treatment of epilepsy. </p> <p>At the time of review, we have not been able to obtain IPD for the remaining five included trials with a total of 1215 participants. For three trials including 753 individuals (<a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>), the trial sponsor confirmed that data could not be made available. For the other two trials, we made contact with the authors/sponsors who expressed interest in collaborating in this IPD meta‐analysis but at the time of writing, no data had been received (<a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>). </p> <p>If IPD are received from these trials, we will include the data in future updates. We were able to extract aggregate data from four out of the five trial publications to include in meta‐analysis for our primary outcome of 'time to treatment failure,' resulting in a similar pooled estimate to that from IPD only. Therefore, we do not believe that our failure to obtain IPD from 32% of eligible participants from the five trials has had a large impact on the applicability of the results of the review. We do, however, encourage caution when interpreting the numerical results of the review, particularly longer‐term remission outcomes for which only two trials were of sufficient duration. Given the results of this meta‐analysis it could be that, compared to carbamazepine, the initial doses of lamotrigine chosen were too low. Hence lamotrigine fared better for treatment failure as the dose chosen caused comparatively fewer side effects but was less effective at preventing seizures. This highlights the importance of measuring longer‐term seizure outcomes such as time to one‐ or two‐year remission from seizures, which would be much less affected by initial drug titration and initial target doses. </p> <p>We have good evidence from previous reviews conducted by the Cochrane Epilepsy Group that misclassification of seizure type, particularly generalised seizure types, is an important issue in epilepsy trials (<a href="./references#CD001031-bbs2-0062" title="NevittSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenytoin monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2017, Issue 2. [DOI: 10.1002/14651858.CD001911.pub3] ">Nevitt 2017b</a>; <a href="./references#CD001031-bbs2-0068" title="NolanSJ , MarsonAG , WestonJ , Tudur‐SmithC . Carbamazepine versus phenobarbitone monotherapy for epilepsy: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 12. [DOI: 10.1002/14651858.CD001904.pub3] ">Nolan 2016b</a>; <a href="./references#CD001031-bbs2-0070" title="NolanSJ , MarsonAG , PulmanJ , Tudur SmithC . Phenytoin versus valproate monotherapy for partial onset seizures and generalised onset tonic‐clonic seizures: an individual participant data review. Cochrane Database of Systematic Reviews2016, Issue 4. [DOI: 10.1002/14651858.CD001769.pub3] ">Nolan 2016d</a>). It is also likely in this review that a large proportion of individuals who were classified as experiencing generalised onset seizures at baseline had their seizure type wrongly classified, meaning that the results of the original trials and therefore the results of this review may have been confounded by classification bias. Following sensitivity analyses to account for this potential misclassification, the overall conclusions for our primary and secondary outcomes were not changed (see <a href="#CD001031-sec-0100">Summary of main results</a>). However, due to the small proportion of total participants included experiencing generalised onset seizures (302 out of 2572, 12% of total participants) and up to 50% of those participants with potentially misclassified seizure type, the results of this review are primarily applicable to participants with focal onset seizures. </p> </section> <section id="CD001031-sec-0102"> <h3 class="title" id="CD001031-sec-0102">Quality of the evidence</h3> <p>The nine trials for which IPD were made available (as well as additional trial design information from trial authors/sponsors) were of generally good quality. Less information was available for trials without IPD available where risk of bias assessments were made only based on published information. Six trials were of a double‐blind design (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), and eight trials were of an open‐label design (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). The results of this review suggest that the design of a trial (double‐blind versus open‐label) may influence the withdrawal and treatment failure rates of the trial, an outcome that is subjective and can be influenced by the participant or clinician. It is argued that an open‐label design is more pragmatic and reflective of 'real world' treatment for a trial of a chronic condition such as epilepsy where treatments are likely to be taken long‐term by participants (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>), and it is shown in this review that a significantly higher proportion of participants failed treatment in the trials with a double‐blind design compared to the open‐label trials (45% versus 34%, P &lt; 0.0001, see <a href="#CD001031-sec-0082">Effects of interventions</a>). However, in a trial of a 'new' compared to a 'standard' intervention, knowledge of the treatment allocation may influence the choice of the participant or clinician to continue taking the treatment, which may then influence the perceived effectiveness of the two drugs under comparison. Therefore, we have considered an open‐label design to potentially introduce bias into the results for the subjective outcomes of time to treatment failure, but not for the objective secondary outcomes of time to first seizure and remission. </p> <p>Due to this potential risk of bias from an open‐label design, we have rated the evidence provided in this review according to Grading of Recommendations Assessment, Development and Evaluation (GRADE) criteria for our primary outcome of 'time to treatment failure' as 'moderate' for all participants and the subgroup of participants with focal onset seizures. Due to the limited number of participants with generalised onset seizures (and potential misclassification of seizure type), we have rated this evidence as low quality for the primary outcome (see <a href="./full#CD001031-tbl-0001">summary of findings Table for the main comparison</a>). </p> <p>For our secondary (objective) outcomes of time to first seizure and remission, we have rated the evidence as high‐quality (moderate‐quality in the subgroup of generalised onset seizures for the reasons stated above) (see <a href="./full#CD001031-tbl-0002">summary of findings Table 2</a>). </p> </section> <section id="CD001031-sec-0103"> <h3 class="title" id="CD001031-sec-0103">Potential biases in the review process</h3> <p>We were able to include individual participant data (IPD) for 2572 out of 3787 eligible participants (68%) from nine out of 14 trials in this review and we were able to analyse all outcomes using IPD. Such an approach has many advantages, such as allowing the standardisation of definitions of outcomes across trials, and attrition and reporting biases are reduced as we can perform additional analyses and calculate additional outcomes from unpublished data. For the outcomes we used in this review that are of a time‐to‐event nature, an IPD approach is considered to be the 'gold standard' approach to analysis (<a href="./references#CD001031-bbs2-0072" title="ParmarMK , TorriV , StewartL . Extracting summary statistics to perform meta‐analyses of the published literature for survival endpoints. Statistics in Medicine1998;17(24):2815‐34. ">Parmar 1998</a>). </p> <p>For reasons outside of our control, we were unable to obtain IPD for 1215 participants from five trials for inclusion in this review. However, following sensitivity analyses using aggregate data, we do not believe that the exclusion of 32% of eligible participants is likely to have impacted on the conclusions of this review (see <a href="#CD001031-sec-0101">Overall completeness and applicability of evidence</a>). </p> <p>Finally, we made some assumptions in the statistical methodology used in this review. Firstly, when we received only follow‐up dates and seizure frequencies, we used linear interpolation to estimate. We are aware that an individual's seizure patterns may be non‐linear; therefore, we recommend caution when interpreting the numerical results of the seizure‐related outcomes. </p> <p>We also made an assumption that treatment effect for each outcome did not change over time (proportional hazards assumption, see <a href="#CD001031-sec-0059">Data synthesis</a>). We are aware that in trials of long duration (e.g. <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>, and <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>, of over one year duration), the assumption of treatment effect remaining constant over time may not be appropriate; for example, there is likely to be a difference between participants who achieve immediate remission compared with participants who achieve later remission, and we encourage that results should be interpreted with this limitation in mind. </p> </section> <section id="CD001031-sec-0104"> <h3 class="title" id="CD001031-sec-0104">Agreements and disagreements with other studies or reviews</h3> <p>To our knowledge, together with previous versions of this review, this is the only systematic review and meta‐analysis that compares lamotrigine and carbamazepine monotherapy for focal onset seizures and generalised onset tonic‐clonic seizures. A network meta‐analysis has been published (<a href="./references#CD001031-bbs2-0061" title="NevittSJ , SudellM , WestonJ , Tudur SmithC , MarsonA . Antiepileptic drug monotherapy for epilepsy: a network meta‐analysis of individual participant data. Cochrane Database of Systematic Reviews2017, Issue 12. [DOI: 10.1002/14651858.CD011412.pub3] ">Nevitt 2017a</a>), comparing all direct and indirect evidence from lamotrigine, carbamazepine and other standard and new antiepileptic drugs licensed for monotherapy. The results of this review generally agree with the results of the network meta‐analysis. </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD001031-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG01.png" target="_blank"><b></b></a></p> </div><img alt="Study flow diagram." data-id="CD001031-fig-0001" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Study flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG02.png" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included study." data-id="CD001031-fig-0002" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG03.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure for any reason related to treatment (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0003" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 3</div> <div class="figure-caption"> <p>Time to treatment failure for any reason related to treatment (CBZ: Carbamazepine; LTG: Lamotrigine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG04.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to adverse effects (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0004" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 4</div> <div class="figure-caption"> <p>Time to treatment failure due to adverse effects (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG05.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure due to lack of efficacy (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0005" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 5</div> <div class="figure-caption"> <p>Time to treatment failure due to lack of efficacy (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG06.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure for any reason related to treatment ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0006" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 6</div> <div class="figure-caption"> <p>Time to treatment failure for any reason related to treatment ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0007"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG07.png" target="_blank"><b></b></a></p> </div><img alt="Time to treatment failure for due to adverse events ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0007" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 7</div> <div class="figure-caption"> <p>Time to treatment failure for due to adverse events ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine) </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0007">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0008"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG08.png" target="_blank"><b></b></a></p> </div><img alt="Time to first seizure (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0008" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 8</div> <div class="figure-caption"> <p>Time to first seizure (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0008">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0009"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG09.png" target="_blank"><b></b></a></p> </div><img alt="Time to first seizure ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0009" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 9</div> <div class="figure-caption"> <p>Time to first seizure ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0009">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0010"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG10.png" target="_blank"><b></b></a></p> </div><img alt="Time to six‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0010" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 10</div> <div class="figure-caption"> <p>Time to six‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0010">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0011"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG11.png" target="_blank"><b></b></a></p> </div><img alt="Time to six‐month remission ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0011" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 11</div> <div class="figure-caption"> <p>Time to six‐month remission ‐ by seizure type (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0011">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0012"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG12.png" target="_blank"><b></b></a></p> </div><img alt="Time to 12‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0012" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 12</div> <div class="figure-caption"> <p>Time to 12‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0012">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0013"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-AFig-FIG13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-AFig-FIG13.png" target="_blank"><b></b></a></p> </div><img alt="Time to 24‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)" data-id="CD001031-fig-0013" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 13</div> <div class="figure-caption"> <p>Time to 24‐month remission (CBZ: Carbamazepine; LTG: Lamotrigine)</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-fig-0013">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-AFig-FIG13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0014"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-01" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-01.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 1 Time to treatment failure (any reason related to the treatment)." data-id="CD001031-fig-0014" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-01.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 1 Time to treatment failure (any reason related to the treatment). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0014">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0015"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-02" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-02.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 2 Time to treatment failure due to adverse events." data-id="CD001031-fig-0015" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-02.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 2 Time to treatment failure due to adverse events. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0015">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-02.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0016"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-03" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-03.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 3 Time to treatment failure due to lack of efficacy." data-id="CD001031-fig-0016" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-03.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 3 Time to treatment failure due to lack of efficacy. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0016">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-03.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0017"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-04" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-04.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by seizure type." data-id="CD001031-fig-0017" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-04.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.4</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 4 Time to treatment failure (any reason related to the treatment) ‐ by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0017">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-04.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0018"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-05" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-05.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 5 Time to treatment failure due to adverse events ‐ by seizure type." data-id="CD001031-fig-0018" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-05.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.5</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 5 Time to treatment failure due to adverse events ‐ by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0018">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-05.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0019"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-06" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-06.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 6 Time to treatment failure (any reason related to the treatment, with aggregate data)." data-id="CD001031-fig-0019" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-06.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.6</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 6 Time to treatment failure (any reason related to the treatment, with aggregate data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0019">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-06.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0020"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-07" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-07.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 7 Time to treatment failure (any reason related to the treatment) ‐ subgroup analysis (blinding)." data-id="CD001031-fig-0020" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-07.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.7</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 7 Time to treatment failure (any reason related to the treatment) ‐ subgroup analysis (blinding). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0020">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-07.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0021"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-08" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-08.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 8 Time to first seizure." data-id="CD001031-fig-0021" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-08.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.8</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 8 Time to first seizure. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0021">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-08.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0022"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-09" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-09.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 9 Time to first seizure by seizure type." data-id="CD001031-fig-0022" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-09.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.9</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 9 Time to first seizure by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0022">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-09.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0023"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-10" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-10.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 10 Time to first seizure (with aggregate data)." data-id="CD001031-fig-0023" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-10.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.10</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 10 Time to first seizure (with aggregate data). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0023">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-10.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0024"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-11" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-11.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 11 Seizure freedom (whole study)." data-id="CD001031-fig-0024" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-11.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.11</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 11 Seizure freedom (whole study). </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0024">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-11.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0025"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-12" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-12.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 12 Time to 6‐month remission." data-id="CD001031-fig-0025" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-12.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.12</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 12 Time to 6‐month remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0025">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-12.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0026"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-13" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-13.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 13 Time to 6‐month remission by seizure type." data-id="CD001031-fig-0026" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-13.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.13</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 13 Time to 6‐month remission by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0026">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-13.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0027"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-14" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-14.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 14 Seizure freedom at 6 months." data-id="CD001031-fig-0027" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-14.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.14</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 14 Seizure freedom at 6 months. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0027">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-14.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0028"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-15" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-15.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 15 Time to 12‐month remission." data-id="CD001031-fig-0028" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-15.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.15</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 15 Time to 12‐month remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0028">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-15.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0029"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-16" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-16.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 16 Time to 12‐month remission by seizure type." data-id="CD001031-fig-0029" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-16.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.16</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 16 Time to 12‐month remission by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0029">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-16.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0030"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-17" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-17.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 17 Time to 24‐month remission." data-id="CD001031-fig-0030" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-17.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.17</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 17 Time to 24‐month remission. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0030">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-17.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD001031-fig-0031"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/urn:x-wiley:14651858:media:CD001031:CD001031-CMP-001-18" target="_blank"><b></b></a></p> </div> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_t/tCD001031-CMP-001-18.xxx" target="_blank"><b></b></a></p> </div><img alt="Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 18 Time to 24‐month remission by seizure type." data-id="CD001031-fig-0031" src="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-18.png"/> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.18</div> <div class="figure-caption"> <p>Comparison 1 Lamotrigine (LTG) versus carbamazepine (CBZ), Outcome 18 Time to 24‐month remission by seizure type. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-fig-0031">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/media/CDSR/CD001031/image_n/nCD001031-CMP-001-18.png" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD001031-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: lamotrigine compared with carbamazepine for epilepsy (primary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine compared with carbamazepine for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure types) </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> lamotrigine </p> <p><b>Comparison:</b> carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lamotrigine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1144 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1813 days (669 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.71 (0.62 to 0.82)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2481 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine.</p> <p>Treatment failure due to adverse events also occurred significantly earlier on carbamazepine compared to lamotrigine: HR 0.54 (95% CI 0.45 to 0.65, P&lt;0.00001). </p> <p>There was no difference between lamotrigine and carbamazepine in terms of treatment failure due to lack of efficacy: HR 1.03 (95% CI 0.75 to 1.41, P=0.86) </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1149 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to treatment failure was 1699 days (550 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.74 (0.64 to 0.86)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2182 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊝<br/> <b>moderate<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine.</p> <p>Treatment failure due to adverse events also occurred significantly earlier on carbamazepine compared to lamotrigine: HR 0.56 (95% CI 0.45 to 0.68, P&lt;0.00001). </p> <p>Treatment failure due to lack of efficacy was not calculated for focal onset seizures subgroup due to small numbers of individuals withdrawing from treatment for lack of efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure (any reason related to treatment)</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 0 to 1446 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 57 days in the carbamazepine group </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The 25th percentile** of time to treatment failure was 510 days (453 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.51 (0.33 to 0.78)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>299 (6 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>c,d</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> <p>Treatment failure due to adverse events also occurred significantly earlier on carbamazepine compared to lamotrigine: HR 0.49 (95% CI 0.27 to 0.88, P=0.02). </p> <p>Treatment failure due to lack of efficacy was not calculated for focal onset seizures subgroup due to small numbers of individuals withdrawing from treatment for lack of efficacy. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the carbamazepine and lamotrigine groups are calculated at the median time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to treatment failure' between the treatment groups. </p> <p>** The 25th percentile of time to treatment failure (i.e. the time to 50% of participants failing or withdrawing from allocated treatment) is presented for the subgroup with generalised seizures as less than 50% of participants failed / withdrew from treatment, therefore the median time could not be calculated. </p> <p><b>Abbreviations: 95% CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled hazard ratio for all participants adjusted for seizure type.</p> <p>b. Downgraded once due to high risk of bias due to the open‐label design of five trials included in the analysis (<a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a>; <a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>); the design of the trial may have influenced the withdrawal rates. </p> <p>c. Downgraded once due to high risk of bias due to the open‐label design of three trials included in the analysis (<a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>); the design of the trial may have influenced the withdrawal rates. </p> <p>d. Downgraded once due to potential misclassification of generalised onset seizures in up to 50% of participants in the trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings for the main comparison.</span> <span class="table-title">Summary of findings: lamotrigine compared with carbamazepine for epilepsy (primary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table class="summary-of-findings framed" data-id="CD001031-tbl-0002"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: lamotrigine compared with carbamazepine for epilepsy (secondary outcomes)</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Lamotrigine compared with carbamazepine for epilepsy</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign="top"> <p><b>Patient or population:</b> adults and children with focal onset or generalised onset seizures (generalised tonic‐clonic with or without other generalised seizure types) </p> <p><b>Settings:</b> outpatients </p> <p><b>Intervention:</b> lamotrigine </p> <p><b>Comparison:</b> carbamazepine </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Outcomes</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="2" rowspan="1" valign="top"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Relative effect<br/> (95% CI)<sup>1</sup> </b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>No of participants<br/> (trials)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Quality of the evidence<br/> (GRADE)</b> </p> </td> <td align="" class="table-header" colspan="1" rowspan="3" valign="top"> <p><b>Comments</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Assumed risk</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Corresponding risk</b> </p> </td> </tr> <tr class="table-header separated"> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Carbamazepine</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>Lamotrigine</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 232 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 134 days (98 days shorter) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.26 (1.12 to 1.41)<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2476 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> <p><i>Subgroup: focal onset seizures</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 208 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 96 days (112 days shorter) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 1.29 (1.14 to 1.45)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2177 (9 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> <p><i>Subgroup: generalised onset seizures</i> </p> <p>Range of follow‐up: 0 to 853 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 853 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to first seizure was 337 days (516 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.98 (0.65 to 1.48)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (6 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/> <b>low<sup>b,c</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for lamotrigine</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to 12‐month remission</b> </p> <p><i>All participants</i> </p> <p>Range of follow‐up: 0 to 2420 days</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to 12‐month remission was 452 days in the carbamazepine group</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>The median time to 12‐month remission was 538 days (86 days longer) in the lamotrigine group </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR 0.91 (0.77 to 1.07)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>988 (2 trials)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕<br/> <b>high<sup>b</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>HR of less than 1 indicates an advantage for carbamazepine</p> <p>Time to 12‐month remission not presented by seizure type due to small numbers of participants with generalised onset seizures in the two trials </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>* Illustrative risks in the carbamazepine and lamotrigine groups are calculated at the median time to first seizure or time to 12‐month remission (i.e. the time to 50% of participants experiencing a first seizure or 12‐months of remission) within each group across all trials. The relative effect (pooled hazard ratio) shows the comparison of 'time to first seizure' or 'time to 12‐month remission' between the treatment groups. </p> <p><b>Abbreviations: 95% CI</b> : 95% confidence interval; <b>HR</b>: hazard ratio </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>GRADE Working Group grades of evidence<br/> <b>High quality:</b> Further research is very unlikely to change our confidence in the estimate of effect.<br/> <b>Moderate quality:</b> Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/> <b>Low quality:</b> Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/> <b>Very low quality:</b> We are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p>a. Pooled hazard ratio for all participants adjusted for seizure type.</p> <p>b. High risk of bias due to the open‐label design in some of the included trials, however outcomes are objective and unlikely to be influenced by knowledge of drug allocation. No downgrade made. </p> <p>c. Downgraded once due to potential misclassification of generalised onset seizures in up to 50% of participants in the trials. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 2.</span> <span class="table-title">Summary of findings: lamotrigine compared with carbamazepine for epilepsy (secondary outcomes)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0003"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Focal seizures: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Male gender: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Age at entry (years):</b> </p> <p><b>Mean (SD), range</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Aged &gt; 30 and generalised seizures: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Epilepsy duration (years):</b> </p> <p><b>Mean (SD), range</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of seizures in prior</b> </p> <p><b>6 months: median (range)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (63%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (58%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (40%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (42%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35.3 (17.1), 15 to 71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.5 (14.4), 13 to 69</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (3.3), 0 to 17.9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.8 (2.3), 0.3 to 11.0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1 to 490)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 960)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (44%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35 (56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (43%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (48%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30.9 (14.5), 14 to 86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29.1 (13.9), 14 to 81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.4 (3.2), 0 to 19.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.2 (1.8), 0 to 7.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 1020)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 122)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72 (71%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (69%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55 (54%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28 (58%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77.3 (6.1), 65 to 94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>76.2 (5.9), 66 to 88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 163)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4.5 (1 to 108)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (59%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9.2 (2.0), 6 to 13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8.3 (2.1), 5 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.6 (0.9), 0 to 4.5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.5 (0.3), 0 to 1.4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3(2 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (2 to 11)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51 (89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (83%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24 (42%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33 (62%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33.6 (12.6), 16 to 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38.3 (11.5), 16 to 60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(0 to 60)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (0 to 200)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>418 (99.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201 (99.5%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>222 (53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107 (53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.1 (21.7), 2 to 84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27.5 (21.0), 2 to 77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (1 to 9000)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 3600)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150 (65%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87 (72%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127 (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (50%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31.8 (14.0), 12 to 71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32.7 (14.6), 13 to 71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (3.2), 0 to 17.1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2.2 (3.7), 0.26 to 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3(1 to 133)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (1 to 145)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>329 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>333 (99%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>205 (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>204 (55%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36.8 (18.4), 6 to 83</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39.3 (18.4), 5 to 82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>727</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2(0 to 1185)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (0 to 466)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>69 (59%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65 (54%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70.8 (7.5), 60 to 88</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71.8 (6.7), 60 to 89</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 20)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 (1 to 90)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="19"> <div class="table-footnote"> <p>CBZ = carbamazepine, LTG = lamotrigine; n = number of participants; NA = not applicable; SD = standard deviation </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Demographic characteristics of trial participants (trials providing individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0004"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline neurologic characteristics of participants (trials providing individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>EEG normal: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>CT scan normal: n (%)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Neurological exam</b> </p> <p><b>normal: n (%)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Missing</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32 (46%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30 (46%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (84%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44 (90%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62 (89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61 (92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (73%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (56%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34 (77%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (79%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 (92%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52 (83%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39 (39%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23 (48%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 (58%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (65%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3 (7%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (88%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37(90%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40 (98%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31 (54%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27 (51%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36 (63%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38 (72%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53 (100%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9 (53%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4 (44%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>325</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11 (73%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5 (83%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>330</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202 (89%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103 (85%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>756</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>756</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277 (75%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>281 (76%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45 (38%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37 (31%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (22%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26 (21%)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="10"> <div class="table-footnote"> <p>CBZ = carbamazepine; CT = computerised tomography; EEG = electroencephalogram; LTG = lamotrigine; n = number of participants; NA = not applicable </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Baseline neurologic characteristics of participants (trials providing individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0005"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of participants included in analyses (trials providing individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number randomised</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to treatment failure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to 6‐</b> </p> <p><b>month remission<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to 12‐</b> </p> <p><b>month remission</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Time to 24‐</b> </p> <p><b>month remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a><sup>1</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>150</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a><sup>1,2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>622</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>419</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>621</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a><sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>756</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>754</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>755</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a><sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>239</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>117</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>233</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1479</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1093</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2572</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1477</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1092</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2569</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1476</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1088</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2564</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1476</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1088</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2564</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>494</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>494</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>988</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>377</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>378</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>755</b> </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="19"> <div class="table-footnote"> <p>CBZ = carbamazepine; LTG = lamotrigine; NA: not applicable (trial duration not sufficient to measure the outcome). </p> <p>1. <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>, and <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>, are of 24 weeks duration (approximately six months). The two trials are not included in the analyses of time to six‐month remission but are included in sensitivity analysis of seizure freedom at six months. </p> <p>2. Follow‐up data are missing for one participant in <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>. </p> <p>3. Treatment failure time missing for two participants and seizure data after follow‐up missing for one participant in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>. </p> <p>4. Seizure data after follow‐up missing for six participants in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Number of participants included in analyses (trials providing individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0006"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="2" rowspan="2" valign=""> <p><b>Reason for early</b> </p> <p><b>termination<sup>1</sup> </b> </p> </td> <td align="" bgcolor="#ffffff" colspan="6" rowspan="1" valign=""> <p><b>Classification in time‐to‐event analyses: Event</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="5" rowspan="1" valign=""> <p><b>Classification in time‐to‐event analyses: Censored</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Adverse events</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Inadequate</p> <p>response/seizure recurrence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Both adverse events and inadequate response</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol violation/non‐compliance</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Withdrew consent/participant choice<sup>3</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> <p>(treatment‐related)<sup>4</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Illness or death (not treatment‐related)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Remission of seizures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lost to follow‐up</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Other</p> <p>(not treatment‐related)<sup>5</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Completed trial</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>63</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>102</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="2" valign=""> <p><a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a><sup>2</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>LTG</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>24</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>11</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>52</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>165</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>252</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>CBZ</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>22</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>0</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>85</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign=""> <p>122</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>57</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a><sup>7</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>339</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>420</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>202</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>192</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>90</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>200</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>68</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>93</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a><sup>8</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>181</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>151</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>378</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a><sup>2</sup> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>88</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>LTG</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>118</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>CBZ</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="14" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>251</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>105</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1447</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2144</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>373</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>905</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1624</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Total (all)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>624</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>122</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>157</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>127</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>44</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2352</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3768</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="14"> <div class="table-footnote"> <p>1. Primary reason for discontinuation specified ‐ participants may have withdrawn from allocated treatment for a combination of reasons. </p> <p>2. Reasons for treatment failure extracted from trial publications for <a href="./references#CD001031-bbs2-0005" title="GiladR , SadehM , RapoportA , DabbyR , BoazM , LamplY . Monotherapy of lamotrigine versus carbamazepine in patients with post stroke seizure. Clinical Neuropharmacology2007;30(4):189‐95. ">Gilad 2007</a>, <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a>, and <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>. Individual participant data for reasons for treatment failure provided for other trials. </p> <p>3. Withdrawal of consent/participant choice classified as an event in this review but censored in included trial (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Sensitivity analysis classifying withdrawal of consent as a censored observation did not change the conclusions (results available on request). </p> <p>4. Other treatment‐related reasons: investigator choice (<a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>), drug‐related death, pregnancy or perceived remission (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Specified only as 'other reason' for <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0006" title="Korean Lamotrigine Study Group. An Open, Randomized, Multicenter Comparative Clinical Trial of Lamotrigine and Carbamazepine as Initial Monotherapy in Previously Untreated Epilepsies. Journal of Korean Epilepsy Society2008;12(1):27‐34. ">Korean Lamotrigine Study Group 2008</a>; <a href="./references#CD001031-bbs2-0011" title="SaetreE , PeruccaE , IsojarviJ , Gjerstad L and LAM 40089 Study Group. An international multicenter randomized double‐blind controlled trial of lamotrigine and sustained‐release carbamazepine in the treatment of newly diagnosed epilepsy in the elderly. Epilepsia2007;48(7):1292‐302. ">Saetre 2007</a> and <a href="./references#CD001031-bbs2-0013" title="SteinhoffBJ , UeberallMA , SiemesH , KurlemannG , SchmitzB , Bergmann L and the LAM‐SAFE Study Group. The LAM‐SAFE Study: Lamotrigine versus carbamazepine or valproic acid in newly diagnosed focal and generalised epilepsies in adolescents and adults. Seizure2005;14(8):597‐605. ">Steinhoff 2005</a>. </p> <p>5. Other reasons (not treatment‐related): epilepsy diagnosis changed (<a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>). Specified only as 'other reason' for <a href="./references#CD001031-bbs2-0010" title="RowanAJ , RamsayRE , CollinsJF , PryorF , BoardmanKD , UthmanBM , et al and The V. A. Cooperative Study Group. New onset geriatric epilepsy: a randomised study of gabapentin, lamotrigine and carbamazepine. Neurology2005;64(11):1868‐73. ">Rowan 2005</a>, and for seven participants in <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>. </p> <p>6. No information on whether participants withdrew from treatment or completed the study available for 19 participants </p> <p>7. One participant (randomised to LTG) with date and reason for treatment failure missing. </p> <p>8. Two participants with date of treatment failure missing so not included in analysis of time to treatment failure but with reasons for treatment failure provided (both censored: one withdrew from LTG due to remission of seizures, one withdrew from CBZ due to 'other' non‐treatment‐related reason). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Reasons for premature discontinuation (treatment failure)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0007"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis ‐ Reunanen 1996</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Treatment</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Comparator</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>N</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time to treatment failure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Time to 6‐month remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>HR (95% CI)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>P value</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine (both arms)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59 (0.35 to 0.99)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.04</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.24 (0.86 to 1.79)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.84 (0.36 to 1.95)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.68</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 200 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 100 mg + carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.47 (0.25 to 0.86)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.02</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.96 (0.67 to 1.36)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.62 (0.24 to 1.58)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.32</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 100 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 200 mg + carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>351</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.05 (0.63 to 1.75)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.85</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.29 (0.91 to 1.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.33 (0.56 to 3.17)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.52</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 200 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.41 (0.21 to 0.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.007</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.12 (0.73 to 1.72)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.59</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.63 (0.22 to 1.78)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.39</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lamotrigine 100 mg</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>115</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Carbamazepine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>121</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>236</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.73 (0.43 to 1.26)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.37 (0.90 to 2.07)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1.10 (0.41 to 2.92)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0.86</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="11"> <div class="table-footnote"> <p>mg= milligrams per day; HR = hazard ratio; 95% CI = 95% confidence interval</p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Sensitivity analysis ‐ Reunanen 1996</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0008"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ misclassification of seizure type</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"></td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to treatment failure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to first seizure</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Time to 6‐month remission</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Original analysis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.74, 95% CI (0.64 to 0.86)</p> <p>G: HR 0.51, 95% CI (0.33 to 0.78)</p> <p>O: HR 0.71, 95% CI (0.62 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 1.29, 95% CI (1.14 to 1.45)</p> <p>G: HR 0.98, 95% CI (0.65 to 1.48)</p> <p>O: HR 1.26, 95% CI (1.12 to 1.41)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.87, 95% CI (0.77 to 1.00)</p> <p>G: HR 0.78, 95% CI (0.55 to 1.11)</p> <p>O: HR 0.86, 95% CI (0.76 to 0.97)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of subgroup differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 2.73, df = 1 (P = 0.10), I² = 63.4%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.53, df = 1 (P = 0.22), I² = 34.5%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.37, df = 1 (P = 0.54), I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised onset and age at onset &gt; 30 reclassified<br/> as focal onset </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.72, 95% CI (0.62 to 0.83)</p> <p>G: HR 0.58, 95% CI (0.32 to 1.06)</p> <p>O: HR 0.71, 95% CI (0.62 to 0.82)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 1.25, 95% CI (1.11 to 1.41)</p> <p>G: HR 1.17, 95% CI (0.67 to 2.04)</p> <p>O: HR 1.25, 95% CI (1.11 to 1.40)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.85, 95% CI (0.75 to 0.97)</p> <p>G: HR 0.69, 95% CI (0.44 to 1.08)</p> <p>O: HR 0.84, 95% CI (0.74 to 0.95)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of subgroup differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.45, df = 1 (P = 0.50), I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.06, df = 1 (P = 0.81), I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 0.80, df = 1 (P = 0.37), I² = 0%</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"></td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Generalised onset and age at onset &gt; 30 reclassified<br/> as uncertain seizure type </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.74, 95% CI (0.64 to 0.86)</p> <p>G: HR 0.58, 95% CI (0.32 to 1.06)</p> <p>U: HR 0.62, 95% CI (0.39 to 0.97)</p> <p>O: HR 0.72, 95% CI (0.63 to 0.83)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 1.29, 95% CI (1.14 to 1.45)</p> <p>G: HR 1.17, 95% CI (0.67 to 2.04)</p> <p>U: HR 0.88, 95% CI (0.58 to 1.33)</p> <p>O: HR 1.24, 95% CI (1.11 to 1.39)</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>F: HR 0.87, 95% CI (0.77 to 1.00)</p> <p>G: HR 0.69, 95% CI (0.44 to 1.08)</p> <p>U: HR 0.89, 95% CI (0.60 to 1.31)</p> <p>O: HR 0.86, 95% CI (0.76 to 0.97)</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Test of subgroup differences</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.15, df = 2 (P = 0.56), I² = 0%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 3.03, df = 2 (P = 0.22), I² = 33.9%</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chi² = 1.02, df = 2 (P = 0.60), I² = 0%</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>CI = confidence interval; F = focal onset seizures; G = generalised onset seizures; HR = hazard ratio; O = overall pooled result adjusted by seizure type; U = uncertain seizure type. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Sensitivity analysis ‐ misclassification of seizure type</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0009"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of adverse events experienced (seven trials providing detailed individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="2" valign="top"> <p><b>Trial</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number experiencing</b> </p> <p><b>adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of</b> </p> <p><b>adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>Number of adverse events</b> </p> <p><b>per person (range)</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of drug‐related</b> </p> <p><b>adverse events<sup>1</sup> </b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of adverse</b> </p> <p><b>events requiring action/</b> </p> <p><b>treatment change</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="3" rowspan="1" valign="top"> <p><b>Number of patients</b> </p> <p><b>needing a treatment</b> </p> <p><b>change/dose change</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Total</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>388</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>322</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>710</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>94</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>167</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>111</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>278</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>285</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>576</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>206</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>91</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>511</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>109</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>73</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>182</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>92</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>158</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>66</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0004" title="EunSH , EunBL , LeeJS , HwangYS , KimKJ , LeeYM , et al. Effects of lamotrigine on cognition and behavior compared to carbamazepine as monotherapy for children with partial epilepsy. Brain and Development2012;34(10):818‐23. ">Eun 2012</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0007" title="LeeS‐A , KimMJ , LeeH‐W , HeoK , ShinD‐J , SongH‐K , et al. The effect of recurrent seizures on cognitive, behavioral, and quality‐of‐life outcomes after 12 months of monotherapy in adults with newly diagnosed or previously untreated partial epilepsy. Epilepsy &amp; Behavior2015;53:202‐8. LeeSA , LeeHW , HeoK , ShinDJ , SongHK , KimOJ , et al. Cognitive and behavioral effects of lamotrigine and carbamazepine monotherapy in patients with newly diagnosed or untreated partial epilepsy. Seizure2011;20(1):49‐54. ">Lee 2011</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>218</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>524</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>277</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>801</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>238</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>152</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>390</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>116</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>198</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>124</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>201</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>451</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>694</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>138</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>169</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>307</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>156</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>208</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>260</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>489</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1038</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1339</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2377</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>NA</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>447</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>665</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1112</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>173</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>293</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>120</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>110</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>230</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>779</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>770</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1549</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 to 30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>291</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>382</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>673</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>147</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>159</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>306</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>129</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="18"> <div class="table-footnote"> <p>CBZ = carbamazepine; LTG = lamotrigine; NA = information not available.</p> <p>1. In <a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>, <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a> and <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a> adverse events that are "definitely related", in <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a> and <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a> "a reasonable possibility" that adverse events are treatment‐related and in <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a> adverse events are "related, probably related or possibility related". </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 7.</span> <span class="table-title">Summary of adverse events experienced (seven trials providing detailed individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0009">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0010"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Most commonly occurring adverse events (trials providing detailed individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Most commonly occurring adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. "><b>Brodie 1995 A</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. "><b>Brodie 1995 B</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. "><b>Brodie 1999</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. "><b>Nieto‐Barrera 2001</b> </a> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Accidental injury/fracture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aggression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia/weight loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety/depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aphasia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ataxia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest infection/bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cold/influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concentration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough/wheeze</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizzy/faint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsy/fatigued</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal disturbances</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hair loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache/migraine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>52</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impotence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased/worsened seizures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney/urinary problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood/behavioural change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pins and needles/tingling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash/skin problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep problems/dreams</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Throat/tonsil infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor/twitch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual disturbance/nystagmus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="17"> <div class="table-footnote"> <p>Table of most commonly occurring adverse events split into two for formatting reasons.</p> <p>Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the same type of adverse event multiple times). </p> <p>LTG = lamotrigine; CBZ = carbamazepine</p> <p>Most common adverse events are defined as events reported 10 or more times in at least one of the seven trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Less commonly reported adverse events are not summarised in this table but details are available on request from the review authors. General terminology for the type of adverse events was defined by the review authors based on the individual participant data provided. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 8.</span> <span class="table-title">Most commonly occurring adverse events (trials providing detailed individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0010">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD001031-tbl-0011"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Most commonly occurring adverse events continued (trials providing detailed individual participant data)</span></div> <tbody> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="3" valign="top"> <p><b>Most commonly occurring adverse events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. "><b>Reunanen 1996</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. "><b>SANAD A 2007</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] "><b>Werhahn 2015</b> </a> </p> </td> <td align="left" bgcolor="#ffffff" colspan="4" rowspan="1" valign="top"> <p><b>Total (across seven studies)</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>LTG</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="2" rowspan="1" valign="top"> <p><b>CBZ</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Events</b> </p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Ppts</b> </p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Accidental injury/fracture</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aggression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anorexia/weight loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Anxiety/depression</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>98</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>84</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Aphasia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Ataxia</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Chest infection/bronchitis</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cold/influenza</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>78</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Concentration</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confusion</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Cough/wheeze</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dental</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Dizzy/faint</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>64</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>62</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>243</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>161</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>216</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Drowsy/fatigued</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>125</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>72</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>267</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>123</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>51</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>228</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>562</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>338</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Gastrointestinal disturbances</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>45</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>199</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>145</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>172</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>126</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Hair loss</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Headache/migraine</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>74</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>95</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>97</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>48</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>31</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>40</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>412</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>229</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>264</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>146</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Impotence</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Increased/worsened seizures</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>41</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>86</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>58</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>136</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>75</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>60</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Kidney/urinary problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Memory problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>67</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>87</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Menstrual problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mood/behavioural change</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>61</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>82</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Nausea/vomiting</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>11</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>38</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>35</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>30</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>37</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>179</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>163</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>107</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>15</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>55</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>162</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>103</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Pins and needles/tingling</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>29</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Rash/skin problems</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>26</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>17</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>14</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>36</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>99</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>65</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>20</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>39</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>258</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>183</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>269</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>191</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Sleep problems/dreams</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>24</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>19</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>18</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>132</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>104</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Throat/tonsil infection</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>54</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>43</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>23</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Tremor/twitch</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>12</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>16</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>9</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>53</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>27</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Visual disturbance/nystagmus</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>6</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>7</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>5</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>33</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>22</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>8</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>71</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>50</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>70</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>47</p> </td> </tr> <tr> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Weight gain</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>0</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>13</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>21</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>4</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>34</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>25</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49</p> </td> <td align="left" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>28</p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="17"> <div class="table-footnote"> <p>Table of most commonly occurring adverse events split into two for formatting reasons.</p> <p>Events = number of adverse events reported; Ppts = number of participants reporting the adverse event (a participant could report the same type of adverse event multiple times). </p> <p>LTG = lamotrigine; CBZ = carbamazepine</p> <p>Most common adverse events are defined as events reported 10 or more times in at least one of the seven trials (<a href="./references#CD001031-bbs2-0001" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 A</a>; <a href="./references#CD001031-bbs2-0002" title="BrodieMJ , RichensA , YuenAWC , for UK Lamotrigine/Carbamazepine Monotherapy Trial Group. Double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy. Lancet1995;345(8948):476‐9. GillhamR . Use of SEALS, a quality of life instrument, in evaluating lamotrigine and carbamazepine monotherapy. Epilepsia1995;36 (Suppl 3):S186‐7. GillhamR , KaneK , Bryant‐ComstockL , BrodieMJ . A double‐blind comparison of lamotrigine and carbamazepine in newly diagnosed epilepsy with health‐related quality of life as an outcome measure. Seizure2000;9(6):375‐9. ">Brodie 1995 B</a>; <a href="./references#CD001031-bbs2-0003" title="BrodieMJ , GiorgiL , and the Lamotrigine Elderly Study Group. A multicenter double‐blind randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. Epilepsia1998;39 (Suppl 6):72, Abstract no: D.08. BrodieMJ , OverstallPW , GiorgiL . Multicentre, double‐blind, randomised comparison between lamotrigine and carbamazepine in elderly patients with newly diagnosed epilepsy. The UK Lamotrigine Elderly Study Group. Epilepsy Research1999;37(1):81‐7. BrodieMJ , ReadCL , GillhamRA , SweetRM , KaneK . Lack of neuropsychological effects of lamotrigine compared to carbamazepine as monotherapy. Epilepsia1999;40 (Suppl 2):94. ">Brodie 1999</a>; <a href="./references#CD001031-bbs2-0008" title="Nieto‐BarreraM , BrozmanovaM , CapovillaG , ChristieW , PedersenB , KaneK , et al. A comparison of monotherapy with lamotrigine or carbamazepine in patients with newly diagnosed partial epilepsy. Epilepsy Research2001;46(2):145‐55. ">Nieto‐Barrera 2001</a>; <a href="./references#CD001031-bbs2-0009" title="ReunanenM , DamM , YuenAW . A randomised open multicentre comparative trial of lamotrigine and carbamazepine as monotherapy in patients with newly diagnosed or recurrent epilepsy. Epilepsy Research1996;23(2):149‐55. SeveriS , BianchiA , ZoloP , MuscasGC . Lamotrigine monotherapy in patients with partial epilepsy. Epilepsia1995;36 (Suppl 3):S113. SeveriS , CantelmiT , BianchiA , ZoloP . Efficacy and safety of lamotrigine in patients with partial epilepsy: preliminary data. Bollettino Lega Italiana Contro L'Epilessia1993;82‐3:139‐43. SeveriS , MuscasGC , BianchiA , ZoloP . Efficacy and safety of lamotrigine monotherapy in partial epilepsy. Bollettino Lega Italiana Contro L'Epilessia1994;86‐7:149‐51. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Canadian Journal of Neurological Sciences1993;20 (Suppl 4):S150. YuenAWC , ChapmanA . Interim report on an open multicentre lamotrigine (Lamictal) versus carbamazepine monotherapy trial in patients with epilepsy. Epilepsia1993;34 (Suppl 2):159. ">Reunanen 1996</a>; <a href="./references#CD001031-bbs2-0012" title="MarsonAG , Al‐KharusiAM , AlwaidhM , AppletonR , BakerGA , ChadwickDW , et al and SANAD Study group. The SANAD study of effectiveness of carbamazepine, gabapentin, lamotrigine, oxcarbazepine, or topiramate for treatment of partial epilepsy: an unblinded randomised controlled trial. Lancet2007;369(9566):1000‐15. ">SANAD A 2007</a>; <a href="./references#CD001031-bbs2-0014" title="WerhahnKJ , TrinkaE , DobesbergerJ , UnterbergerI , BaumP , Deckert‐SchmitzM , et al. A randomized, double‐blind comparison of antiepileptic drug treatment in the elderly with new‐onset focal epilepsy. Epilepsia2015;56(3):450‐9. [DOI: 10.1111/epi.12926] ">Werhahn 2015</a>). Less commonly reported adverse events are not summarised in this table but details are available on request from the review authors. General terminology for the type of adverse events was defined by the review authors based on the individual participant data provided. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 9.</span> <span class="table-title">Most commonly occurring adverse events continued (trials providing detailed individual participant data)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/full#CD001031-tbl-0011">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD001031-tbl-0012"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lamotrigine (LTG) versus carbamazepine (CBZ)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1 Time to treatment failure (any reason related to the treatment) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.73 [0.64, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2 Time to treatment failure due to adverse events <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2569</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.54 [0.45, 0.65]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">3 Time to treatment failure due to lack of efficacy <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1874</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.75, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">4 Time to treatment failure (any reason related to the treatment) ‐ by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2481</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.71 [0.62, 0.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.1 Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.74 [0.64, 0.86]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>4.2 Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.51 [0.33, 0.78]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">5 Time to treatment failure due to adverse events ‐ by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2466</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.55 [0.45, 0.66]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.1 Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2182</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.56 [0.45, 0.68]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>5.2 Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>284</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.49 [0.27, 0.88]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">6 Time to treatment failure (any reason related to the treatment, with aggregate data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.63, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">7 Time to treatment failure (any reason related to the treatment) ‐ subgroup analysis (blinding) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>13</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3391</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.70 [0.63, 0.78]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.1 Double‐blind</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1231</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.65 [0.56, 0.75]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>7.2 Open‐label</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2160</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.76 [0.65, 0.90]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">8 Time to first seizure <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2564</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.22 [1.09, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">9 Time to first seizure by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2476</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.26 [1.12, 1.41]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.1 Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>9</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>2177</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.29 [1.14, 1.45]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>9.2 Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>6</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>299</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.98 [0.65, 1.48]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">10 Time to first seizure (with aggregate data) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>12</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3216</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.24 [1.12, 1.37]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">11 Seizure freedom (whole study) <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.11 [1.04, 1.18]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">12 Time to 6‐month remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1793</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.84 [0.74, 0.94]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">13 Time to 6‐month remission by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1708</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.76, 0.97]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.1 Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>7</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>1454</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.87 [0.77, 1.00]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>13.2 Generalised</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>5</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>254</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.78 [0.55, 1.11]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">14 Seizure freedom at 6 months <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>14</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>3760</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.96 [0.89, 1.03]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">15 Time to 12‐month remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">16 Time to 12‐month remission by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>988</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.90 [0.76, 1.07]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.1 Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>894</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.91 [0.77, 1.09]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>16.2 Uncertain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.81 [0.47, 1.37]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">17 Time to 24‐month remission <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.00 [0.80, 1.25]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">18 Time to 24‐month remission by seizure type <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>755</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.03 [0.82, 1.30]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.1 Focal</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>661</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.06 [0.83, 1.35]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>18.2 Uncertain</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>94</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Hazard Ratio (Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.86 [0.44, 1.67]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Lamotrigine (LTG) versus carbamazepine (CBZ)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD001031.pub4/references#CD001031-tbl-0012">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD001031.pub4&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD001031-note-0004">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD001031-note-0005">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD001031-note-0003">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD001031-note-0002">Bahasa Malaysia</a> </li> <li class="section-language"> <a class="" href="ru#CD001031-note-0001">Русский</a> </li> <li class="section-language"> <a class="" href="zh_HANS#CD001031-note-0018">简体中文</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734739000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734739000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773542000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773465000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739773471000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001031\x2epub4"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001031\x2epub4"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001031\x2epub4"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD001031\x2epub4\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD001031\x2epub4"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734739000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=QO4KtYGW&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001031.pub4&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD001031.pub4';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD001031.pub4/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD001031.pub4/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD001031.pub4%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740728046241"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001031.pub4/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740728046245"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD001031.pub4/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918ebae8f88ef498',t:'MTc0MDcyODA0Ni4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 